Drug, bio-affecting and body treating compositions inventions 12/05

20050288211 - Chemotactic factor inhibitor for modulating inflammatory reactions: The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by...

20050288213 - Combination therapy for the treatment of obesity: and an anti-obesity agent, useful for the treatment and prevention of diabetes, obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides...

20050288212 - Components of the presenilin-complex: The present invention is based on a novel direct interaction between a Presenilin and a novel protein identified herein and named Sambiasin-1, a homolog thereof named Sambiasin-2, as well as a protein complex further comprising a Nicastrin. Also comprised are uses of said components and complexes, as well as methods...

20050288215 - Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure: The present invention provides methods of treating cardiac hypertrophy by administering a drug that is known to be a non-selective inhibitor of nuclear protein export to patient in need thereof....

20050288214 - Nucleotide sequence encoding ptd and cea fusion protein, tat-cea fusion protein, anti-tumor vaccine and pharmaceutical composition for treating tumor comprising the fusion protein: A nucleotide sequence encoding a fusion protein of PTD and CEA. The nucleotide sequence includes a CEA-encoding nucleotide sequence into which a PTD-encoding nucleotide sequence is inserted....

20050288217 - Method for enhancing or inhibiting insulin-like growth factor-i: The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same....

20050288216 - Novel transformed cell, method of screening antiaging agent and antiaging agents: This invention provides a novel transformed cell useful in constructing an anti-aging agent screening system, a screening method which uses the same and an anti-aging agent, and it relates to a transformed cell in which a gene coding for (a) a protein capable of phosphorylating p38 protein, or (b) p38...

20050288220 - Erythropoietin with high specific activity: The invention concerns new EPO compositions with high specific activity which are characterized by a high proportion of N-acetyl-lactosamine units or/and tetraantennary branches in the carbohydrate structure. In addition the invention concerns a process for producing such EPO products....

20050288218 - Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof: The present invention is based, at least in part, on the discovery that the amino terminal domain and the N-linked carbohydrate contained in the amino terminal of C1INH are required for binding of C1INH to LPS. C1INH has the ability to block the binding of LPS to cells, e.g., macrophages....

20050288219 - Osteoprotegerin in milk: The present invention pertains to osteoprotegerin obtainable from milk sources, in particular human and bovine milk. The present invention also relates to the use thereof for preparing an ingestible preparation and/or a pharmaceutical composition, in particular to the use of such a preparation/composition for preventing or treating disorders associated with...

20050288221 - Glycopeptide antibiotics: e

20050288222 - Methods for enhancing the bioavailability of a drug: The invention provides methods and compositions for enhancing the bioavailability of a drug in a subject. The present invention also provides methods and compositions for treating or preventing hepatic injury in a subject in need thereof. The invention further provides methods for identifying hydrophobic peptides, e.g., β-amyloid peptide derivatives, which...

20050288228 - Bile-acid conjugates for providing sustained systemic concentrations of drugs: This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds....

20050288226 - Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1): This invention provides compositions, methods and kits for the diagnosis and treatment of cancers wherein Wnt Inhibitory Factor-1 (WIF-1) is underexpressed....

20050288225 - Modulators of intracellular inflammation, cell death and cell survival pathways: A B1 protein, its isoforms, analogs, fragments and derivatives, are provided. The protein is useful in the modulation of intracellular inflammation, cell death and/or cell survival pathways....

20050288224 - Novel protein, a gene coding therefor and a method of using the same: The object of the present invention is to screen and identify a novel antimicrobial protein which can inhibit the growth of plant pathogenic microorganisms at a relatively low concentration such as Pyricularia oryzae and Rhizoctonia solani causative of two major diseases causing damage to rice crops and, further, to clone...

20050288223 - Obg3 fragments inhibiting the conversion of active obg3 into less active obg3 and other compositions for treatment of metabolic disorders: The present invention relates to the field of obesity research. Fragments of OBG3 have been identified that reduce weight gain in animals. These fragments of OBG3 should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and...

20050288227 - Use of thioredoxin measurements for diagnostics and treatments: The invention relates to methods for monitoring patient response to histone deacetylase inhibitors (e.g., suberoylanilide hydroxamic acid (SAHA)) or other therapeutic agents by measuring the level of thioredoxin in body fluids, tissues, and/or cells, such as peripheral blood mononuclear cells, plasma, or serum. The invention also relates to methods of...

20050288229 - Connective tissue stimulating peptides: Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG”and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein “P” in the motif is proline or hydroxyproline and the peptide stimulates the development,...

20050288230 - Non-steroidal anti-androgen therapy: The present invention relates to a method of enhancing bone mineral density (BMD) in a patient in need thereof by administration of an effective amount of a non-steroidal anti-androgen compound, preferably bicalutamide. Further aspects of the invention include methods of treating prostate cancer in patients at increased risk of bone...

20050288231 - Biologically active peptides as glutamate receptor inhibitors: The present invention relates to biologically active peptides derived from the neurite outgrowth-promoting domain of luminin-1, i.e. the γ1-chain of laminin-1. These peptides include the decapeptide RDIAEIIKDI (SEQ ID NO: 1) and the truncated peptides derived therefrom comprising the biologically active domain thereof, the tripeptide KDI. The invention is directed...

20050288233 - Novel compounds as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease....

20050288234 - Novel use of peptide compounds for treating essential tremor and other tremor syndromes: The present invention is directed to the use of a class of peptide compounds for treating essential tremor and other tremor syndromes....

20050288232 - Proline ester and preparation containing the same for percutaneous administration: The proline ester (I) of the present invention and a pharmaceutically acceptable salt thereof are useful as a prodrug of enalaprilat, which is a medicine useful for preventing or treating circulatory diseases such as hypertension, cardiac diseases (e.g., cardiac hypertrophy, cardiac failure, and myocardial infarct), nephritis, and apoplexy. Thus, a...

20050288235 - Novel pharmaceutical compositions for treating and saving and the method for the preparation thereof: The present invention relates to a pharmaceutical composition and the method for the preparation thereof. The composition comprises 1.5˜6.9% (w/v) of one or more substances selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, and the like, and 3˜18% (w/v) of one or more substances...

20050288236 - Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death: This patent discloses a composition comprising a substituted fullerene, wherein the substituted fullerene comprises a fullerene core (Cn), wherein n is an even integer greater than or equal to 60, and at least one substituent group bonded to at least one carbon atom of the fullerene core, and at least...

20050288237 - Novel derivative of flavone c-glycoside and composition containing the same: The present invention relates to novel flavone C-glycoside derivatives or salts thereof, especially those showing an anti-allergic effect, and compositions containing them. Recently, cases of allergic diseases, especially pollenosis and atopic dermatitis have increased to such a degree that they have become a social problem. Flavones and their glycosides have...

20050288239 - Anticancer glycoside compounds: The present invention relates to new classes of anti-cancer compounds. In particular, the present invention provides glycoside compounds as anti-cancer agent, alone, or in combination with other anti-cancer agents or therapies....

20050288238 - Benzocyclodecane derivatives with antitumor activity: C1-C6 alkylaminosulfonyl and arylaminosulfonyl group; with the provisos that if R1 and R4 ═O, then one of R2, R3, R5, R6 and R13 is not H atom; or a pharmaceutically acceptable salt thereof. These benzocyclodecane derivatives are endowed with antitumor activity; a process and new intermediates for their preparation, the...

20050288240 - Novel-prodrugs for phosphorus-containing compounds: M is selected from the group that attached to PO32−, P2O63−, or P3O94− is a biologically active agent, and is attached to the phosphorus in formula I via a carbon, oxygen, sulfur or nitrogen atom; and pharmaceutically acceptable prodrugs and salts thereof....

20050288247 - Inducible inactivation of synaptic transmission: The invention provides molecular systems for inducible and reversible inactivation of synaptic transmission. These systems can be used for studying neuronal networks and for treating conditions involving abnormally high neuronal activity or excitotoxic damage....

20050288245 - Methods and compositions for reducing viral genome amounts in a target cell: Methods and compositions for reducing viral genome amounts in a target cell are provided. In the subject methods, the activity of a miRNA is inhibited in a manner sufficient to reduce the amount of viral genome in the target cell, e.g., by introducing a miRNA inhibitory agent in the target...

20050288243 - Methods and compositions for treating gain-of-function disorders using rna interference: The present invention relates to novel methods for treating dominant gain-of-function diseases. The invention provides methods for targeting regions of the copper zinc superoxide dismutase (SOD1), which causes inherited amyotrophic lateral sclerosis (ALS), with RNAi agent. The invention further provides RNAi resistant replacement genes containing mismatches with their respective RNAi...

20050288241 - Novel polypeptides and nucleic acids encoded thereby: Disclosed are novel polypeptides and nucleic acids encoding same. Also disclosed are vectors, host cells, antibodies and recombinant methods for producing the polypeptides and polynucleotides, as well as methods for using same....

20050288244 - Oligonucleotides comprising a c5-modified pyrimidine: One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a...

20050288246 - Peptide conjugated, inosine-substituted antisense oligomer compound and method: A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which...

20050288248 - Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders....

20050288242 - Rna interference mediated inhibition of ras gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating RAS, e.g. K-RAS, H-RAS, and/or N-RAS gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RAS,...

20050288249 - Isoform specific inhibition for treatment of pain and reduction of anesthetic threshold: Several lines of evidence have shown a role for the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway in the development of spinal hyperalgesia. However, the roles of effectors for cGMP are not fully understood in the processing of pain in the spinal cord. cGMP-dependent protein kinase (PKG) Iα but...

20050288250 - Novel use of carbohydrates and compositions: A process for preventing colon fermentation imbalance by the administration of a composition of a slowly fermented carbohydrate complex oligomer or polymer. A method of preparing the composition by nutritionally, nutraceutically and/or pharmacologically formulating the carbohydrate oligomer or polymer is an aspect of this process....

20050288252 - Composition for stimulating bone growth and differentiation and method for isolating same: This invention relates to isolated heparan sulphate and use thereof to stimulate bone cell growth and differentiation. The invention also relates to use of heparan sulphate with implants, prosthesis and bioscaffolds to repair and regenerate bone. Such use may be for repair of damaged tissue including bone tissue, for example...

20050288251 - Treatment and prevention of abnormal cellular proliferation: This invention provides a method for inhibiting or preventing the abnormal growth of cells, including transformed cells, by administering an effective amount of O-acylated heparin derivative. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanism (e.g. loss of contact inhibition). This includes the abnormal growth of:...

20050288253 - Boronic acid salts: Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound....

20050288255 - Modulation of lysophosphatidylcholine and treatment of diet-induced conditions: The present invention provides methods for the treatment of lysophosphatidylcholine-related conditions. In particular, the invention provides a method of treating an insulin-related condition, e.g., diabetes or diabetes type 2, and/or a weight-related-condition, e.g., unwanted weight gain or obesity, in an animal subject by reducing production, absorption and/or activity of lysophosphatidylcholine....

20050288254 - Novel therapeutical use of agonist ligands specific to g2a receptor: The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC...

20050288256 - Methods for preparing p2x7 inhibitors: e

20050288257 - Novel stable compositions of water and oxygen sensitive compounds and their method of preparation: The present application described a new formulation for oxygen and/or water sensitive compounds with an inert material such as paraffin. The new formulation provides stability for the oxygen and/or water sensitive compounds in the air and can be handled easily. The new formulation of the present invention is useful as...

20050288258 - Compounds, compositions and methods for treating or preventing viral infections and associated diseases: Pyridine derivatives that exhibit antiviral activity are disclosed....

20050288259 - Composition: The present invention relates primarily to an effective long-term simultaneous control of louse infestations and prevention of blowfly strikes on sheep and goats using a specific oil-in-water or water-in-oil topical suspoemulsion formation comprising an insecticidally effective amount of each of the two active ingredients diflubenzuron and dicyclanil and sutiable carriers...

20050288260 - Novel nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same: The present invention relates to nitric oxide-releasing amidine diazeniundiolates, compositions comprising same, methods of using same, and a method for preparing same from imidate diazeniumdiolates and primary or secondary amines....

20050288261 - Compositions and method for treating infection in cattle and swine: Novel formulations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, with a fluorinated chioramphenicol or thiamphenicol derivative antibiotic such as florfenicol are disclosed. Methods for using such formulations in the treatment and prevention of infectious diseases of bovines and swine, including bovine respiratory disease and swine respiratory disease, are...

20050288262 - 3, 10, and 12a substituted tetracycline compounds: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation...

20050288263 - 2-(&agr;-hydroxypently) benzoate and its preparation and use: The invention relates to new synthetic 2-(α-hydroxypentyl) benzoates, their preparation and pharmaceutical compositions containing such salts as active ingredients. The invention also relates to the use of the compounds for preventing and treating cardioischemia, cerebroischemia and cardiac or cerebral arterial occlusion (obstruction), etc....

20050288264 - Dosage regimen and pharmaceutical composition for emergency contraception: The invention relates to a dosage regimen for emergency contraception, to pharmaceutical compositions of the same purpose, to the use of levenorgestrel for the manufacture of pharmaceutical compositions for the same purpose, as well as to the manufacturing process of these pharmaceutical compositions. According to the invention the emergency...

20050288266 - Combinations comprising antimuscarinic agents and corticosteroids: Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic...

20050288265 - Novel combination of glucocorticoids and pde-4 inhibitors for treating respiratory diseases, allegic diseases, asthma and copd: The invention relates to a novel combination of a glucocorticoid, especially loteprednol, and at least one phospho-diesterase-4 inhibitor (PDE-4-inhibitor), especially hydroxyindole-derivative N-(3,5-dichloropyridine-4-yl)-2-[1-(4-fluorbenzyl)-5-hydroxyindole-3-yl]-2-oxoacetamide, for a simultaneous, sequential or separate administration in the treatment of respiratory diseases, allergic diseases, asthma and chronic obstructive pulmonary diseases (COPD)....

20050288267 - Estradiol prodrugs: e

20050288268 - Preparation of 6-hydroxyequilenins: This invention relates to a process for the preparation of 6-hydroxyequilenins, which are useful as estrogenic agents....

20050288269 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase...

20050288270 - New aminopyridine derivatives and their use as pharmaceuticals: which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD;...

20050288271 - Arylsulfonamides and uses related thereto: Arylsulfonamide compounds of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:...

20050288272 - Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1 receptor antagonists: A combination therapy for cardiovascular diseases, in particular essential hypertension, pulmonary hypertension and/or congestive heart failure, involving administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one AT1 receptor antagonist....

20050288273 - Antibacterial agents: Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including...

20050288274 - Treating rhinitis by topically administering an epinastine solution to the nasal mucous membrane: A method for treating allergic rhinitis, comprising topically administering to the nasal mucus membrane of a host in need of such treatment a solution comprising: epinastine, optionally in the form of its racemate, its enantiomers, or its pharmacologically acceptable acid addition salts, in a pharmacologically acceptable carrier....

20050288275 - New compounds: The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system....

20050288276 - Pharmaceutical formulation of olanzapine: A pharmaceutical formulation comprising a homogeneous mixture of (a) olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a monosaccharide and/or oligosaccharide, (c) a polysaccharide and, optionally, further ingredients....

20050288278 - Hiv replication inhibiting pyrimidines: the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or...

20050288277 - Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (s)-2,3-benzodiazepine: The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress which are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility, gastrointestinal inflammation, visceral hypersensitivity, or gastric ulcers....

20050288279 - Phenothiazine derivatives and their method of use: Novel phenothiazine derivatives and their use in the treatment of diabetes mellitus (type I and type II), and as an ovulation inhibitor (contraceptive), cancer chemotherapeutic and/or prophylactic agent, anti-obesity drug (body weight regulator), and immunostimulant....

20050288280 - Meloxicam in veterinary medicine: A veterinary pharmaceutical formulation containing meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more vehicles having analgesic efficacy for the treatment of inflammatory painful diseases, particularly for the treatment of mild or moderate mastitis cases. The treatment leads to an effective long...

20050288281 - Hetero isonipecotic modulators of vanilloid vr1 receptor: This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals....

20050288282 - Inhibitors of histone deacetylase: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions....

20050288284 - Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors: The invention relates to ethynyl-substituted tetrahydroquinolinone derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are group I mGluR modulators and are therefore useful for the control and prevention of acute and/or chronic...

20050288283 - Topical formulations for treating allergic diseases: Methods for topically treating allergic diseases of the eye, ear or nose using tricyclic compounds are disclosed....

20050288285 - Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses: wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and...

20050288286 - Anti-inflammatory medicaments: Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds....

20050288287 - Chiral cis-imidazolines: and the pharmaceutically acceptable salts and esters thereof, wherein X1, X2, X3, Y1, Y2 and R are described herein inhibit the interaction of MDM2 protein with a p53-like peptide and hence have anti proliferative activity....

20050288288 - Methods for preparing p2x7 inhibitors: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R4, and R7 have any of the values as defined in the specification. The compounds are useful as agents in the treatment of diseases, including inflammatory diseases such as rheumatoid arthritis. Also provided are compositions of crystalline 2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2R-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide comprising less than...

20050288290 - Fused heterocyclic kinase inhibitors:

20050288289 - Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors: The present invention is directed to intermediates that are useful for preparing pyrrolotriazines, and processes for preparing such intermediates....

20050288291 - Modulation of cell fates and activities by phthalazinediones: Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth,...

20050288293 - 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors: 8-Hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds are inhibitors of HIV integrase and inhibitors of HIV replication. More particularly, the compounds are of Formula (1): wherein R1, R2, R3, R4, R5 and R6 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in...

20050288296 - Alkyl substituted indoloquinoxalines: H

20050288295 - Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof:

20050288294 - Inhibitors of akt activity: The present invention is directed to compounds which contain a five-membered heterocyclic ring fused to a substituted pyrazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration...

20050288292 - Pharmaceutical formulation and its use in the treatment of inner ear diseases: A new pharmaceutical formulation, especially for trans-tympanic or intra-transtympanic administration, containing a quinoxalin-2-one compound of the formula (I) in which R1 and R2, independently of one another, are hydrogen, methyl-, ethyl-, propyl-, butyl- or R1 and R2 together are a cyclo-alkyl compound; R3 is methoxy, ethoxy, hydroxy, hydrogen, C1-C4 alkyl...

20050288297 - Quinazoline derivatives as kinase inhibitors: The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the...

20050288298 - Methods for the treatment of synucleinopathies: Methods are provided of treating synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease and Multiple System Atrophy, comprising administering to a synucleinopathic subject one or more farnesyl transferase inhibitor compounds....

20050288299 - Azaindole derivatives as inhibitors of p38 kinase: The invention is directed to methods to inhibit p38 kinase, preferably p38-α using compounds which are azaindoles wherein the azaindoles are coupled through a piperidine or piperazine type linker to another cyclic moiety....

20050288300 - Methods of use fluoroquinolone compounds against maxillary sinus pathogenic bacteria: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against maxillary sinus pathogenic pathogenic bacteria....

20050288301 - Novel crystalline forms of gatifloxacin: Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of gatifloxacin, in particular forms omega and T2RP....

20050288302 - Novel crystalline forms of gatifloxacin: Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of gatifloxacin, in particular forms omega and T2RP....

20050288303 - Cyclic protein tyrosine kinase inhibitors: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders....

20050288304 - Tetrahydronaphthylpiperazines as 5ht1b antagonists, inverse agonists and partial agonists: and D is a group of the formula D, wherein Y, W and Z are C or N and wherein R7 is as defined herein and their salts and compositions which include selective antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors. Compounds of the invention are useful...

20050288308 - 11b-hsd1 inhibitors for the treatment of diabetes: d

20050288307 - Anti-viral compounds: The present invention relates to the use of 2-substituted 4-heteroaryl-pyrimidines and related compounds in the treatment of viral disorders....

20050288306 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well...

20050288305 - N-biarylmethyl aminocycloalkanecarboxamide derivatives: N-Biarylmethylainocycloalkanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway....

20050288309 - Fungicidal mixtures: in which n is 1 or 2 and X is halogen, alkyl or haloalkyl, where the radicals X may be different if n is 2, in a synergistically effective amount, methods for controlling harmful fungi using mixtures of the compounds I and II, compositions comprising these compounds and the use...

20050288310 - Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors: A method of treating a cellular proliferative in a patient through the use of a naphthalimide and a PARP-1 inhibitor is disclosed. In a one embodiment, the naphthalimide is amonafide or an analog thereof....

20050288311 - Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same: m

20050288312 - Bicyclic pyridine and pyrimidine p38 kinase inhibitors:

20050288313 - Pyrrolo[2,3-d]pyrimidine compounds: wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer,...

20050288314 - 2,4-diaminoquinazolines for spinal muscular atrophy: e

20050288315 - Dual molecules containing a peroxide derivative, synthesis and therapeutic applications thereof: Rx or Ry is a cyclic peroxide with 4 to 8 chain links, which may comprise 1 or 2 additional oxygen atoms in the cyclic structure, and one or more substituents R3, identical or different, at least one representing a halogen atom, an —OH group, a —CF3 group, an aryl,...

20050288317 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or...

20050288316 - Beta-carbolines as growth hormone secretagogue receptor (ghsr) antagonists: wherein R3-R8, X, and Y are as described herein, processes for preparing the compounds, pharmaceutical compositions comprising the compounds, and use of the compounds and compositions in the prophylaxis or treatment of a GHSR receptor-related disorder. Examples of such disorders are obesity and related disorders such as diabetes type II,...

20050288319 - Ccr1 antagonists and methods of use therefor: e

20050288318 - Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics:

20050288320 - Imidazonaphthyridines: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed....

20050288321 - Kinase inhibitors: The present invention provides kinase inhibitors of Formula (I)....

20050288322 - Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone: The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone....

20050288323 - Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine: The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions....

20050288324 - Aromatic sulfonamides as peroxynitrite-rearrangement catalysts: The invention relates to the use of aromatics sulfonamides of the general formula I as peroxynitrite rearrangement catalysts, to the preparation thereof and to the use thereof as medicament for the treatment of various disorders....

20050288325 - Therapy for andropause using estrogen agonists/antagonists and testosterone: The present invention concerns the treatment of andropause and related conditions using a combination of an estrogen agonist/antagonist and testosterone....

20050288326 - Combination therapy: The present invention relates to a combination therapy for treating an HIV infection or inhibiting integrase comprising (S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxymethyl-2-methylpropyl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (“Compound A”) or a pharmaceutically acceptable solvate or salt thereof in combination with at least one other anti-HIV agent. In some embodiments of the present invention, the other anti-HIV agents are...

20050288327 - Small molecule inhibitors of her2 expression: Peptide mimetic small molecule inhibitors of Sur-2 are provided having the general formula:...

20050288329 - 2-methylprop anamides and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or...

20050288328 - Selective serotonin receptor inverse agonists as therapeutics for disease: Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-insomnia agent. Disclosed herein are also methods of treating insomnia using the disclosed pharmaceutical compositions....

20050288330 - Process for producing a polymorphic form of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride): The present invention discloses a novel, stable polymorph of 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and it's polymorph Form (VI)....

20050288331 - Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease: The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with...

20050288333 - Controlling angiogenesis with anabaseine analogs: Compounds controlling angiogenesis and vasculogenesis. In particular, induction of angiogenesis to promote growth of new vasculature by the use of anabaseine agonists and to the reduction of pathological angiogenesis by the use of anabaseine antagonists....

20050288332 - Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2ylmethyl)piperidin-4-yl]-1h- pyrrole mono-hydrochloride: The present invention relates to crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-yl-methyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride salt, a pharmaceutical formulation containing said salt and to methods for treating cancer and for inhibiting tumor growth using said salt....

20050288334 - Process for preparing optically pure active compounds: The invention relates to a novel process for preparing an optically pure PPI having a sulfinyl structure using a chiral zirconium complex or a chiral hafnium complex....

20050288335 - Triamide-substituted heterobicyclic compounds: e

20050288336 - Cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine protease, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them....

20050288337 - Novel compounds: The present invention relates to novel pyridone derivatives capable of inhibiting α4 integrin mediated cell adhesion, processes for their preparation, compositions comprising them and their use in the treatment of diseases capable of being modulated by the inhibition of cell adhesion....

20050288338 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor MR, and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or...

20050288339 - Medicinal compositions containing diuretic and insulin resistance-improving agent: The present invention relates to a pharmaceutical composition comprising an insulin sensitizer and a diuretic which can prevent or treat side effects such as edema, cardiac enlargement, body fluid retension or hydrothorax caused by administration of an insulin sensitizer....

20050288340 - Substituted heteroaryl- and phenylsulfamoyl compounds: The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including...

20050288341 - Novel diphenyl ether derivatives: Novel diphenyl ether derivatives are provided that exhibit activity useful for reducing glucose, cholesterol, and/or triglyceride levels in plasma, and for treatment of obesity, inflammation, immunological diseases, autoimmune diseases, diabetes and disorders associated with insulin resistance....

20050288342 - Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides: v

20050288343 - Process of preparing substituted carbamates and intermediates thereof: An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided....

20050288346 - Acetophenone potentiators of metabotropic glutamate receptors: The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed...

20050288344 - Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infection....

20050288345 - Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases: Compounds, compositions and methods are provided for the prophylaxis and treatment of infections caused by viruses of the Pneumovirinae subfamily of Paramyxoviridae and diseases associated with such infections....

20050288347 - Certain triazole-based compounds, compositions, and uses thereof: Thiotriazole-based chemical entities exhibiting ATP-utilizing enzyme inhibitory activity, methods of using such chemical entities, and compositions comprising such chemical entities, are described....

20050288349 - Cancer treatments and pharmaceutical compositions therefor: wherein R is selected from the group consisting of H, carboxyl (—CO2H), hydroxyl, amino or esters (—CO2R′) wherein R′ is selected from the group consisting of alkoxy, haloalkyl, alkenyl, and cycloalkyl wherein the alkyl groups have from 1-8 carbons or CH3CH2(OCH2CH2)n— or CH3CH2CH2(OCH2CH2CH2)n— or (CH3)2CH—(OCH(CH3)CH2)n— wherein n is from 1-3,...

20050288348 - Compounds and methods for use thereof in the treatment of cancer: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator....

20050288350 - Bicyclic androgen and progesterone receptor modulator compounds and methods: The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by AR and PR. More particularly, the invention relates to nonsteroidal compounds and compositions that are high affinity, high specificity agonists, partial agonists (i.e., partial activators and/or tissue-specific activators) and antagonists for AR and PR....

20050288351 - Azaspiro compounds for the treatment of pain: This invention relates to azaspiro compounds and their use as medications especially for the treatment of chronic, chronic-phlogistic and/or neuropathic pain. A compound that lends itself particularly well to the production of analgesics is 2-azaspiro[4.6]undecane-3-thion....

20050288352 - [3.2.0] heterocyclic compounds and methods of using the same: Compounds of Formulae I-VI and derivatives thereof having anti-cancer, anti-inflammatory, and anti-microbial properties and to compositions that include one or more of compounds and their derivatives or analogs having anti-cancer, anti-inflammatory and anti-microbial properties are disclosed. Pharmaceutical compositions comprising such compounds and methods of treating cancer, inflammatory conditions, and microbial...

20050288353 - Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity c-kit kinase....

20050288354 - Ppar active compounds: Compounds are described that are active on PPARs, including pan-active compounds. Also described are methods for developing or identifying compounds having a desired selectivity profile....

20050288355 - Combination therapy wherein a serotonin reuptake inhibitor is used: The invention relates to the use of a compound, which is a serotonin reuptake inhibitor, and another compound, which is a GABAB receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized...

20050288356 - Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics: wherein: R1 represents a C3-C10 alkyl, a C5-C10 carbocyclic radical that is unsubstituted or substituted one or more times with a methyl group; R2 represents a hydrogen atom or a (C1-C4)alkyl group; R3 represents a halogen atom or a (C1-C4)alkyl group; R4 represents a hydrogen or halogen atom or a...

20050288357 - Gamma lactams as prostaglandin agonists and use thereof: 1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or...

20050288358 - 3-amino-2-phenylpyrrolidine derivatives: 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed....

20050288359 - Agents and methods for the treatment of disorders associated with oxidative stress: The invention provides a method for preventing or reducing the effects of oxidative stress on a substrate. The method includes the step of treating the substrate with a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein: R1 is one or more substituents selected from —H, -alkyl, -alkoxy,...

20050288361 - Dendrite elongation inhibitor for melanocyte and skin preparation for external use containing the same: e

20050288360 - Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone: Compositions comprising epigallocatechin gallate and 4-(4-hydroxyphenyl)-2-butanone may be used for the treatment or prevention of obesity or conditions associated with obesity such as non-insulin-dependent diabetes mellitus (NIDDM, type II) and syndrome X. The compositions may find use in the nutritional field as a supplement to food and beverages, as well...

20050288362 - Use of tocotrienols for elevating ikbkap gene expression and treating familial dysautonomia: The present invention provides methods for elevating IKBKAP gene expression and the level of functional IKAP protein in cells, which are beneficial to human individual, such as an individual suffering from Familial Dysautonomia, by providing one or more tocotrienols alone or in combination with one or more tocopherols to the...

20050288363 - Therapeutic compositions and methods of use: Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis....

20050288364 - Halogenated triptolide derivatives as immunomodulators and anticancer agents: m

20050288365 - Platinum complexes and methods for inhibiting tumor cell proliferation: The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus...

20050288366 - Novel aminodicarboxylic acid derivatives: e

20050288367 - Benzyloxy derivatives as maob inhibitors: n, m, and o are as defined in the specification. The compounds are selective monoamine oxidase β inhibitors and are useful for the treatment and prevention of Alzheimer's disease and senile dementia, as well as other CNS disorders. The invention also relates to processes for preparing such compounds and pharmaceutical...

20050288368 - Compositions and methods for treating and preventing necrosis: A method for treating and/or preventing cell necrosis and diseases associated therewith, comprising the inhibition of one or more elastase enzymes within said cells....

20050288369 - Novel n-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions comprising the same: The present invention relates to novel n-hydroxythiourea, urea and amide compounds as a potent vanilloid receptor antagonist and the pharmaceutical compositions comprising the same. The inventive compound can be useful for analgesics to prevent, alleviate or treat pain diseases or inflammatory disease comprising pain, acute pain, chronic pain, neuropathic pain,...

20050288370 - Novel forms of pravastatin sodium: New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of...

20050288371 - Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis: The present invention relates to the use of gaboxadol for the preparation of medicaments useful for the treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis....

20050288373 - Methods of treating various conditions by administration of sustained release l-arginine: The present invention provides methods for using L-arginine formulations, such as sustained release formulations, for various indications, including lowering triglyceride levels, inducing thermogenesis, weight loss and treatment and prevention of obesity and obesity related conditions, such as diabetes. Moreover, the present invention provides methods for treating or preventing other indications,...

20050288372 - Methods of treating various conditions by administration of sustained released l-arginine: The present invention provides methods for using L-arginine formulations, such as sustained release formulations, for various indications, including lowering triglyceride levels, inducing thermogenesis, weight loss and treatment and prevention of obesity and obesity related conditions, such as diabetes. Moreover, the present invention provides methods for treating or preventing other indications,...

20050288374 - Chemical stabilization of solubilized retinoids and aqueous compositions comprised thereof: Solubilized retinoids within cosmetic/pharmaceutical compositions, e.g., aqueous gels or oil-in-water emulsions, are chemically stabilized by introducing therein an amount of at least one base effective to salify such retinoids; the resultant compositions are useful in cosmetics and dermatology, e.g., for treating acne vulgaris or psoriasis....

20050288375 - Method and composition for treating neurodegenerative disorders: The invention provides compositions and methods for treating neurodegenerative disorders. A method of the invention involves administering to an individual in need of treatment a composition having an R-NSAID and an NMDA antagonist. Another method of the invention involves administering to an individual in need of treatment a composition having...

20050288376 - Bicyclyl or heterobicyclylmethanesulfonylanimo-substituted n-hydroxyformamides: e

20050288377 - Use of calcimimetic as an adynamic bone disease related treatment: The present invention relates to monitoring and treatment of adynamic bone disease and related disorders and the consequences of thereof. In one aspect, the present invention is directed to a method for avoiding or reducing soft tissue calcification (or the risk thereof) in a subject afflicted with adynamic bone disease,...

20050288379 - Benzoquinone compounds as anti-cancer agents: e

20050288378 - Cancer chemotherapy:

20050282731 - Administration form for pharmaceutically active peptides with sustained release and method for the production thereof: The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of...

20050282729 - Crisp polypeptides as contraceptives and inhibitors of sperm capacitation: Included in the present invention are methods of inhibiting sperm capacitation, inhibiting the phosphorylation of a protein at tyrosine residues, inhibiting an acrosomal reaction, and inhibiting fertilization of an egg by sperm with the administration of a CRISP polypeptide....

20050282733 - Differentiation modulating agents and uses therefor: The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including,...

20050282736 - Methods for cyclizing synthetic polymers: The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D1-X(n)-D2, where D1 is a first...

20050282732 - Pharmaceutical compositions and treatment methods-7: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of...

20050282734 - Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin: An optically clear, pharmaceutically acceptable aqueous composition comprising paclitaxel or a derivative thereof, serum albumin and a pharmaceutically acceptable vehicle, wherein the composition comprises no more than 10% organic solvent and has a pH of about 3.0 to about 4.8, is described. The serum albumin can be fatted or defatted,...

20050282737 - Procollagen (iii) propeptides and related substances for treating fibrotic diseases: In a method of treating a fibrotic disease, a composition is administered to a mammal an effective amount, wherein the composition contains a polypeptide selected from the group consisting of rat, mouse, and human N-terminal procollagen (III) propeptide and rat, mouse, and human C-terminal procollagen (III) propeptide and further contains...

20050282730 - Thrombopoetin receptor activator and process for producing the same: [wherein each of R1 and R3 is independently a hydrogen atom, SO3H, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-18 arylcarbonyl group (the C1-6 alkyl group, the C1-6 alkylcarbonyl group and the C6-18 arylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a...

20050282735 - Use of plasma proteins concentrates containing vwf with a high proportion of high molecular weight multimers: Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers prevents a bleeding diathesis and reduces pre-, peri- and postoperative blood loss in acquired Von Willebrand syndromes such as in cardiovascular diseases requiring surgical procedures, especially those requiring extracorporeal circulation....

20050282738 - Alpha 1-acid glycoprotein, alpha 2-hs glycoprotein, alpha 1-antitrypsin, and fragments thereof induce apoptosis in cancer cell lines: This invention characterizes the selective apoptotic activity of specially prepared zinc charged alpha 1-acid glycoprotein, alpha 2-HS glycoprotein, and alpha 1-antitrypsin. These proteins cause apoptosis in cancer cells while leaving normal cells intact. In addition, active fragments of zinc charged alpha 1-acid glycoprotein and alpha 2-HS glycoprotein, whether manufactured from...

20050282739 - Metallopeptide compounds: Metallopeptides with a sequence of a biologically active alpha-melanocyte stimulating hormone (α-MSH), gamma-melanocyte stimulating hormone (γ-MSH), or bombesin sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two...

20050282740 - Methods and compositions for regulating protein-protein interactions: The invention relates to methods and compositions of WW-domains as phosphoserine and phosphothreonine binding modules. The WW-domain containing polypeptides of the invention can be used, for example, to regulate cell growth; to treat neurodegenerative diseases; to screen for substances that modulated interactions between WW-domain containing polypeptides and phosphorylated ligands; as...

20050282742 - Formulation of boronic acid compounds: The invention relates to the formulation of pharmaceutical compounds. More particularly, the invention provides stable, pharmaceutically acceptable compositions prepared from boronic acid compounds and methods for preparing the compositions. The invention also provides novel boronate ester compounds. The invention further provides boronic acid anhydride compounds useful in the methods of...

20050282741 - Peptides and their use to ameliorate cell death: There is disclosed novel peptides, fragments or analogues thereof and polynucleotides encoding the same, obtained from streptokinase suitable for use in the amelioration of cell death and methods related thereto....

20050282753 - Bacteriocins and novel bacterial strains: Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry....

20050282744 - Compositions and methods for preventing or treating cancer: The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer....

20050282748 - Glue compositions for lung volume reduction: The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The...

20050282752 - Il-1ra variants: The present invention provides for an IL-1ra having reduced aggregation, methods of reducing aggregation of IL-1ra, and kits comprising an IL-1ra having reduced aggregation....

20050282747 - Methods and compositions for wound healing: Migration-inducing peptide fragments or domains from native human fibronectin are attached through a linker to hyaluronic acid. Such agents are useful for in vivo wound healing, including but not limited to deep wounds and chronic wounds....

20050282743 - Molecular interactions in cells: The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in cells, particularly interactions between a PDZ protein and a PL protein. Reagents and methods that are provided are useful for treatment of a variety of diseases and conditions in a variety of cell types....

20050282745 - Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy: Chicken II and salmon GnRH analog decapeptides resistant to degradation by peptidase incorporating D-arginine, D-leucine, D-tBu-Serine, D-Trp or other active D amino acids at position 6 and ethylamide, aza-Gly-amide or other Gly amide at position 10. The analogs demonstrate preferential binding to male and female reproductive system GnRH receptors. Biopotency...

20050282746 - Novel glutamate receptor and utilization thereof: It is intended to disclose a glutamate sensor in taste sensation and digestion and provide techniques using the same. A glutamate-receptor protein having the following characteristics is reacted with a substance binding thereto in the presence of a test substance and thus the inhibition or acceleration of the reaction is...

20050282751 - Therapeutic agent for renal anemia: There is provided an agent for preventing or treating renal anemia, which contains arginine as an active ingredient. This agent for preventing or treating renal anemia can be easily administered and the administration can be controlled at home to obtain excellent effect in preventing or treating renal anemia....

20050282750 - Treatment for dark adaptation: The present invention addresses the treatment of age-related macular degeneration using regulation of pathogenic mechanisms similar to atherosclerosis. In further specific embodiments, compositions that increase reverse cholesterol transport are utilized as therapeutic targets for age-related macular degeneration. In a specific embodiment, the lipid content of the retinal pigment epithelium, and/or...

20050282749 - Use of glp-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes: The present invention relates to methods for prevention and treatment of bone-related disorders and calcium homeostasis related syndromes using a GLP-2 molecule or GLP-2 activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention...

20050282754 - Peptides and peptide analogues designed from hfe protein and their uses in the treatment of iron overload diseases: The present invention relates to peptides and peptide analogues designed from HFE protein. In particular, it relates to peptides and peptide analogues designed from an alpha-1 region of HFE protein which lowers the binding affinity of transferrin receptor for transferrin. Such compounds mimic HFE protein function, and reduce iron uptake...

20050282755 - Compositions having antimicrobial activity and uses thereof: Provided are compositions and methods useful for reducing microbial populations on and/or in skin, reducing skin inflammation, targeting skin substructures and components, and treating skin conditions such as acne. A composition often comprises an antimicrobial peptidyl moiety having an amino acid sequence conforming to a sequence motif provided herein, and...

20050282756 - Oral delivery of peptide pharmaceutical compositions: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of...

20050282757 - Peptide boronic acid compounds useful in anticoagulation: A method for preventing thrombosis in a setting where rapid onset and/or rapid offset of anticoagulation is required, comprising administering a compound selected from the group consisting of boronic acids which have a neutral thrombin P1 domain linked to a hydrophobic moiety capable of binding to the thrombin S2 and...

20050282758 - 6-11 bicyclic ketolide derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the...

20050282759 - Injectable ready-to-use solutions containing an antitumor anthracycline glycoside: A sealed glass container containing therein a stable, injectable, sterile, pyrogen-free doxorubicin anti-tumor composition in a solution which consists essentially of a physiologically acceptable salt of doxorubicin dissolved in a physiologically acceptable solvent therefore, wherein said solution has not been reconstituted from a lyophilizate, and wherein said solution has a...

20050282760 - Antisense modulation of ptpn12 expression: Antisense compounds, compositions and methods are provided for modulating the expression of PTPN12. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPN12. Methods of using these compounds for modulation of PTPN12 expression and for treatment of diseases associated with expression of PTPN12 are provided....

20050282762 - Antisense oligonucleotides for treating atopic diseases and neoplastic cell proliferation: The present invention relates to the use of antisense oligonucleotides directed against specific nucleic acid sequences coding for receptors, alone or in combination, in order to inhibit the inflammatory reaction that is present in asthma, atopy or hypereosinophilia and to inhibit neoplastic cell proliferation. The antisense oligonucleotides of the present...

20050282766 - Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers: Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and/or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175,...

20050282765 - Enzyme having s-adenosyl-l-homocysteine hydrolase (ahcy) type activity: Enzyme having AHCY-type activity and DNA sequences which encode the enzyme. The enzyme is useful in a screening assay to identify compounds useful as immunosuppression agents....

20050282767 - Inhibitors of epoxide hydrolases for the treatment of hypertension: wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R1—R4 is hydrogen, R2 is hydrogen when X is nitrogen but is not present when X is sulfur...

20050282764 - Method of identifying nucleic acid compositions for muting expression of a gene: The invention provides compositions and methods for muting expression of an endogenous gene in an animal cell, the muting resulting from providing a muting nucleic acid to a cell. The muting nucleic acid comprises a transgene, which is substantially homologous to a portion of the endogenous gene. The portion of...

20050282763 - Methods of treating bladder disorders: Methods of treating bladder disorders, including bladder cancer and inflammatory bladder diseases such as interstitial cystitis are disclosed. The methods include identifying a mammal that has or is at risk for having a bladder disorder and administering isolated nucleic acid sequences to the mammal. Nucleic acids used in the methods...

20050282761 - Modulation of growth hormone receptor expression and insulin-like growth factor expression: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of...

20050282768 - Purine derivatives as adenosine a1 receptor agonists and methods of use thereof: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury,...

20050282769 - Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage: Methods for preventing and treating damage to the optic nerve and/or retina with adenosine kinase inhibitors are disclosed....

20050282774 - Method and pharmaceutical to treat spinal discs: An injectable for injection into a spinal disc, and a method to treat a spinal disc with the injectable. The injectable consists essentially of chondroitin sulfate and glucosamine HCl buffered to a pH above about 6.0....

20050282771 - Methods for treating bleeding disorders using sulfated polysaccharides: Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of...

20050282773 - Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer: Modified polysaccharide compositions and their use in combination with at least one anti-cancer drug for treating subjects with cancer, reduce toxicity and inhibit metastasis, are described. The modified polysaccharide includes a saccharide backbone being less than 5% esterified and containing repeating units, wherein each repeating unit has a plurality of...

20050282772 - New dietary supplement composition for obesity and inflammation: The present invention relates to dietary supplement phytochemical compositions, comprising calcium, potassium double salt of (−)-hydroxycitric acid and glucosamine hydrochloride, and optionally boswellic acids, curcuminoids, 5-hydroxytryptophan, chondroitin sulfate and L-carnitine. The claimed compositions are useful in dietary supplements, nutritional supplements or pharmaceutical preparations for weight loss and inflammatory epidemics....

20050282770 - Synthetic glycosulfopeptides and methods of synthesis thereof: A new class of synthetic glycosulfopeptides (GSPs) which have one or more sulfated tyrosine residues and a glycan linked to the peptide, the glycan preferably including a sialyl Lewisx group or a sialyl Lewisa group. In a preferred version the GSPs have an O-glycan comprising a β1,6 linkage to a...

20050282775 - Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome: A method and medicament for treating inflammation in a patient with a sulfated polysaccharide without inducing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater...

20050282776 - Injectable pharmaceutical compositions comprising sodium diclofenac and beta-cyclodextrin: Injectable pharmaceutical compositions are described comprising sodium diclofenac, a β-cyclodextrin and a polysorbate, suitable for subcutaneous and intramuscular administration....

20050282777 - Dextrinized, saccharide-derivatized oligosaccharides: Disclosed are saccharide-derivatized oligosaccharides. The derivatized oligosaccharides preferably are prepared by extruding a malto-oligosaccharide mixture with a saccharide or mixture of saccharides having a DP ranging from 1 to 4. The products are low in digestibility, and thus in various embodiments are suitable for use as bulking agents, for controlled...

20050282778 - Boron complexation strategy for use in manipulating 1-acyldipyrromethanes: A method of making a metal complex comprises combining a 1-monoacyldipyrromethane with a compound of the formula R1R2MX, wherein M is boron, R1 and R2 are each independently organic substituents; and X is an anion leaving group; to produce a metal complex of the formula DMR1R2 wherein DH is a...

20050282779 - Boron complexation strategy for use in manipulating 1-acyldipyrromethanes: A method of making a metal complex comprises combining a 1-monoacyldipyrromethane with a compound of the formula R1R2MX, wherein M is boron, R1 and R2 are each independently organic substituents; and X is an anion leaving group; to produce a metal complex of the formula DMR1R2 wherein DH is a...

20050282780 - Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding: Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are benzoxazoles and related compounds....

20050282781 - Compositions of stable bioactive metabolites of docosahexaenoic (dha) and eicosapentaenoic (epa) acids: An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce...

20050282782 - Lewis acid mediated synthesis of cyclic esters: Methods for the synthesis of cyclic phosphonic acid diesters from 1,3-diols are described, whereby cyclic phosphonic acid diesters are produced by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid....

20050282783 - Modified phosphocalcic compound, injectable composition containing same: The invention concerns a phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline...

20050282784 - Therapy using a combination of raloxifene and alendronate: Provided are methods of treating bone disease including, but not limited to, osteoporosis, metastatic bone disease, or Paget's disease, by administering a combination of raloxifene and alendronate in a manner that mitigates the formation of ulcerative adverse events....

20050282785 - Topical administration of amifostine and related compounds: The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and/or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio/chemo protectants. The invention is also directed to treatment...

20050282786 - Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations: The present invention is for a method for decreasing C-reactive protein levels (CRP) in a mammal in need thereof. The method comprises administering an effective amount of a non-antibacterial tetracycline formulation, to the mammal. In one embodiment, the non-antibacterial tetracycline formulation is a non-antibacterial amount of an antibacterial tetracycline. In...

20050282787 - Synthesis of tetracyclines and analogues thereof: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines...

20050282789 - 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds: Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone...

20050282788 - Pharmaceutical compositions comprising silicones and two solubilized active principles: Topically applicable, anhydrous and physically/chemically stable pharmaceutical compositions useful for the treatment of disorders of the skin, notably psoriasis, contain a silicone agent; a therapeutically effect amount of a compound A selected from the group consisting of vitamin D or derivative thereof, solubilized in a solvent therefor; and a therapeutically...

20050282790 - Therapeutic gestagens for the treatment of premenstrual dysphoric disorder: This invention describes the use of a therapeutic gestagen (e.g., drospirenone, cyproterone acetate, dienogest) for the production of a pharmaceutical agent for the treatment of premenstrual dysphoric disorder (PMDD), optionally in combination with a natural or synthetic estrogen (e.g., estradiol or ethinylestradiol)....

20050282791 - 18-nor steroids as selectively active estrogens: The invention further describes the use of steroids, on which the gonatriene skeleton is based, for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of the gonatriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bone...

20050282792 - Calcitriol/clobetasol propionate compositions for the treatment of psoriasis: Topically applicable pharmaceutical compositions useful for the treatment of psoriasis contain respective amounts of calcitriol and clobetasol propionate permitting a once-per-day effective regimen of topical application onto the part or parts of the skin affected by psoriasis....

20050282793 - Steroid prodrugs with androgenic action: p

20050282794 - Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium....

20050282795 - Quinolyl organic germanium ester and the synthesis method thereof: The present invention relates to compounds of quinolyl organic germanium ester having the following Formula 1 and the synthesis methods thereof. R1 and R2 are defined in the specification. Organic germanium acyl chloride and 8-hydroxylquinoline were used as the starting raw materials. Displacement reaction was carried out at 0-40° C.,...

20050282796 - Tetracyclic azepinoindole compounds: e

20050282797 - Process for the preparation of oxcarbazepine and related intermediates:

20050282798 - Pharmaceutical compounds:

20050282799 - Method of treating lower urinary tract disorders: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to...

20050282800 - Method of synthesis and isolation of solid n-desmethylclozapine and crystalline forms thereof: Disclosed herein are crystalline Forms A, B, C, D, and E of N-desmethylclozapine, methods of preparing the same, pharmaceutical compositions comprising the same, and methods of therapeutic treatment involving N-desmethylclozapine polymorphic forms....

20050282801 - Novel phenantridine analogues and uses thereof: s

20050282803 - Cis-imidazolines:

20050282802 - Disalt inhibitors of il-12 production: This invention relates to disalt nitrogen-heteroaryl inhibitors of IL-12 production, and related methods and pharmaceutical compositions....

20050282804 - Process for preparing 10alpha-[4'-(s,s-dioxothiomorpholin-1'-yl)]-10-deoxo-10-dihydroartemisinin: i

20050282805 - Five-membered heterocycles useful as serine protease inhibitors: or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation...

20050282806 - Mycophenolate mofetil impurity: Provided is an impurity of mycophenolate mofetil, processes for its preparation and its use as a reference....

20050282807 - Novel thiazoles and methods of their use: This invention concerns novel thiazole compounds. Methods of using these compounds for the treatment, prevention and management of various diseases or disorders, as well as pharmaceutical compositions of these compounds, are also disclosed....

20050282808 - Benzofuran derivative: wherein x is a group of the formula: —N═ or —CH═; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the...

20050282809 - Heteroaryl-hydrazone compounds: or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, prodrug or polymorph thereof wherein X is —C(Rg)═N-A. The invention also relates to methods of treating IL-12 overproduction-related disorders, methods of treating or preventing disorders related with excessive bone loss, methods for inhibiting osteoclast formation, and methods for treating or preventing a...

20050282810 - Oxindole derivatives: The present invention is related to oxindole derivatives, compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition...

20050282811 - Diazabicyclic histamine-3 receptor antagonists: as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I or II, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment...

20050282812 - Inhibitors of cholesteryl ester transfer protein: This invention relates to inhibitors of CETP and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by CETP....

20050282813 - Fused cyclic modulators of nuclear hormone receptor function: wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7′ or NR10, and M′ is a bond or NR10, with the proviso that at least one of M or M′ must be a bond; E is C=Z2, CR7CR7′, SO2, P═OR2,...

20050282814 - Vasculostatic agents and methods of use thereof: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other...

20050282815 - Novel aminobenzamide derivative: R12 is, for example, phenyl, thiazolyl, pyridyl or methylene dioxyphenyl. The compound according to this invention has a glucokinase activation effect, and for example, is useful in the treatment and prevention of diabetes mellitus, and in the prevention of its complications such as diabetic nephropathy, diabetic retinopathy, diabetic neuropathy and...

20050282816 - Pyrazinylmethyl lactam derivatives: wherein R1, R3, R6, R13 X, a, n and m are as defined herein, their pharmaceutically acceptable salts, and pharmaceutical compositions which include selective agonists, antagonists, inverse agonists and partial agonists of serotonin 1 (5-HT1) receptors, specifically, of one or both of the 5-HT1A and 5-HT1B receptors. The compounds of...

20050282817 - Arylpiperazines having activity at the serotonin 1a receptor: A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal....

20050282818 - Ubiquitin ligase inhibitors: This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use...

20050282819 - Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia: i

20050282820 - Processes for preparing gonadotropin releasing hormone receptor antagonists: The present invention relates to methods of making Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists....

20050282821 - Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives: wherein Ar, Y, R1 and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing...

20050282822 - Therapeutic agents: The present invention provides a compound of formula I processes for preparing such compounds, their the utility in treating clinical conditions including lipid disorders (dyslipidemias) whether or not associated with insulin resistance, methods for their therapeutic use and pharmaceutical compositions containing them....

20050282825 - Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient....

20050282823 - Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as...

20050282824 - Substituted pyrimidines as inhibitors of bacterial type iii protein secretion systems: In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial...

20050282826 - Diphenylimidazopyrimidine and -imidazole amines as inhibitors of beta-secretase: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient....

20050282827 - Pyrazolo-pyrimidine derivatives: wherein R1, R2, R3, R4, R5 and p are as defined in the description and to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, to the manufacture of such compounds and compositions, and to methods of treating or preventing acute and/or chronic central nervous system disorders by administering...

20050282828 - Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines: e

20050282829 - Furanopyrimidine compounds as potassium ion channel inhibitors:

20050282830 - Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders: A method of treatment of the human or non-human animal body for treating or preventing MMP-9-dependent disorders is disclosed, for example vascular syndromes, damages or diseases, atherosclerotic damages, arthritic conditions, inflammatory reactions, autoimmune reactions or proliferative diseases, which method comprises administering to a human or non-human animal body in need...

20050282831 - Selective antagonists of a2a adenosine receptors: Selective antagonists of A2A adenosine receptors are provided. The novel A2A blockers are useful for the treatment of Parkinson's disease and other diseases....

20050282832 - Compositions and method for enhancing the therapeutic activity of opioids in treatment of pain: Compositions and methods for inhibiting opioid tolerance and opioid withdrawal-induced hyperalgesia are provided....

20050282833 - Pharmacological treatment of psoriasis: The present invention relates generally to the prevention of psoriatic-related disorders via administration of anti-viral agents or combination of anti-viral agents that possess anti-hyperproliferative pharmacological activity....

20050282834 - Compositions, devices and methods for treating cardiovascular disease: In situ drug-delivering medical devices, materials and associated compounds, pharmaceutical compositions and methods are disclosed for the treatment of diseases of proliferating cells, particularly atherosclerosis and restenosis....

20050282836 - Solid orally ingestible formulations of tetrodotoxin: The present invention refers to outwardly solid or completely solid oral (or designed to be orally ingested) formulations of tetrodotoxin and/or analogs or derivatives thereof....

20050282835 - Vaginal health products: The invention provides compositions and methods for increasing cell growth, stimulating cell turnover and promoting the secretion of mucus within the reproductive tract of a female mammal....

20050282837 - 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues: The embodiments described herein concern 5-substituted pyrimidine derivatives of conformationally locked nucleoside analogues and to the use of these derivatives as anti-viral and anti-cancer agents....

20050282838 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases are disclosed....

20050282840 - Methods of modulating neurotrophin-mediated activity: Disclosed are compositions which modulate the interaction of nerve growth factor and brain-derived neurotrophic factor with neurotrophic receptors. Also disclosed are methods of using the compositions of the invention, including methods of administration....

20050282841 - Novel esters as useful broad spectrum fungicidal compounds: The instant invention relates to the discovery of certain novel fungicidal esters of agriculturally active acids. These esters can present agronomical advantages over traditional fungicidal products by presenting multiple fungicidal mechanisms that ensure activity over a broad fungi spectrum while limiting the appearance of fungi resistance....

20050282839 - Pyrimidyl phosphonate antiviral compounds and methods of use: Pyrimidine I and pyrimidinone II phosphonate compounds and methods for viral inhibition are disclosed. The compounds include at least one phosphonate group covalently attached at any site....

20050282847 - fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines: r

20050282844 - 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines: and pharmaceutical compositions thereof, and methods for controlling the level of one or more inflammation inducing cytokines selected from the group consisting of, interleukin-1 (IL-1), Tumor Necrosis Factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8), thereby controlling, mediating, or abating disease states affected by the level of extracellular inflammatory cytokines in...

20050282846 - Compounds capable of activating cholinergic receptors: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine....

20050282845 - Substituted pyrimidines as selective cyclooxygenase-2 inhibitors: Methods for the treatment of pain, fever, inflammation of a variety of conditions and diseases....

20050282843 - Therapeutic applications of 2-substituted 4-heteroarylpyrimidines: R7 is a group (CH2)n—R8, wherein n is 0, 1, 2, 3 or 4 and wherein R8 is selected from alkyl, aryl, heteroaryl, heterocycloalkyl, F, Cl, Br, I, CF3, NO2, CN, OH, O-alkyl, O-aryl, O-heteroaryl, O-heterocycloalkyl, CO-alkyl, CO-aryl, CO-heteroaryl, CO-heterocycloalkyl, COO-alkyl, NH2, NH-alkyl, NH-aryl, N(alkyl)2, NH-heteroaryl, NH-heterocycloalkyl, COOH, CONH2, CONH-alkyl,...

20050282842 - Therapeutic compounds based on pyrazolopyridine derivatives:

20050282848 - Isoquinoline derivatives and methods of use thereof: The invention provides novel classes of Isoquinoline Derivatives. Pharmaceutical compositions and methods of making and using the compounds, are also described....

20050282849 - Carboline derivatives useful in the treatment of cancer: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor...

20050282850 - Heterotricylic compounds for use as hcv inhibitors: The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inhibit HCV infection of a cell, particular in the form of treating HCV infection in a...

20050282852 - Preventive and therapeutic medicament for gastroesophageal reflux disease: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and...

20050282851 - Substituted (thiazol-2-yl)-amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes: e

20050282854 - Amide substituted imidazopyridines: Imidazopyridine compounds that contain amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases....

20050282853 - Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8,-tetrahydro-imidazo[1,2,-a]pyridines as antiprotozoal agents: A method for treating a microbial infection, including an infection from a protozoan pathogen, such as Trypanosoma brucei rhodesiense and Plasmodium falciparum, in a subject in need thereof by administering to the subject an effective amount of a dicationic imidazopyridine compound or a dicationic tetrahydro-imidazopyridine compound. Processes for synthesizing dicationic...

20050282855 - Susceptibility gene for myocardial infarction, stroke, and paod; methods of treatment: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in...

20050282856 - 3-cyano-quinoline derivatives: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an...

20050282858 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or...

20050282861 - Cannabinoid receptor ligands: e

20050282859 - Dual acting snri-nmda antagonists for the treatment of genitourinary disorders: Discolsed herein are compositions and methods for treatment of genitourinary disorders (e.g., urge incontinence). The compositions may generally include a dual-acting SNRI-NMDA antagonist (e.g., bicifadine and/or milnacipran). Alternatively, the compositions may generally include an SNRI and an NMDA antagonist....

20050282860 - Fexofenadine polymorphs and process for the preparation thereof: The invention provides novel crystalline forms of fexofenadine hydrochloride, a process for the preparation of the novel forms and of the known form A, and their use in therapy....

20050282857 - Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions: wherein A, X and R1 to R3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these...

20050282862 - Aromatic amides: This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor....

20050282863 - Novel-n substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles as selective estrogen receptor modulators: The invention provides a novel class of N-substituted dihydrobenzothiepino, dihydrobenzoxepino and tetrahydro benzocyclohepta indoles and their pharmaceutically acceptable salts, and methods for of synthesizing these compounds. The invention further comprises pharmaceutical compositions and methods of use for these compounds for the treatment of estrogen related diseases or disorders....

20050282864 - Indole derivatives as h3 inverse agonists: wherein X, R1, R2, R3, R4 and R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of...

20050282865 - Neurotrophic factor production promoter: This invention provides a novel neurotrophic factor production promoter containing N-acetyl-L-pipecolic acid or a pharmaceutically acceptable salt thereof as an active ingredient, which can be used for the prophylaxis or treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, spinal injury, Huntington's disease, cerebral infarction, head trauma, multiple sclerosis,...

20050282866 - Substituted indoles: i

20050282867 - Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazo-lidine-2,4-dione: A novel pharmaceutical compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride, a process for preparing such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound in medicine....

20050282868 - Substituted anthranilamides for controlling invertebrate pests: This invention provides compounds of Formula (I), and N-oxides and salts thereof (I) wherein A, B, R1 through R5, R7 through R9, X and Y are as defined in the disclosure. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a...

20050282869 - Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith: There is disclosed the use of triprolidine for enabling an individual to wake refreshed after sleep and the method of treating an individual with triprolidine. Use of triprolidine as active ingredient in the manufacture of a composition for the treatment of sleep disorders is also described. A method of treating...

20050282870 - Peripherally-acting vasodilators: A system for the delivery of chemical vasodilators into the skin for the purpose of increasing the blood flow in a tissue that exhibits compromised circulation. The designated purpose of this increased blood flow is to transiently reverse or inhibit or prevent the onset of an associated medical affliction that...

20050282871 - 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors: The present invention is directed to novel 3-(3,5-disubstituted-4-hydroxyphenyl)-propionamide derivatives that are inhibitors of Cathepsin B. Pharmaceutical composition comprising these compounds, method of treating diseases mediated by Cathepsin B, utilizing these compounds and methods of preparing these compounds are also disclosed....

20050282872 - Novel thyroid receptor ligands and method ii: New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or differential hydrogen, halogen, alkyl...

20050282873 - Epothilone derivative for the treatment of hepatoma and other cancer diseases: The present invention relates to a method of treating a warm-blooded animal, especially a human, having a cancer disease selected from hepatoma; primary fallopian tube cancer; primary peritoneal cancer; breast cancer progressing after treatment with hormonal agents or radiotherapy; renal cell carcinoma progressing after treatment with a cytokine, radiotherapy and/or...

20050282874 - Novel thiazolopyrazoles and methods of their use: This invention concerns novel thiazolopyrazole compounds and compositions comprising them. Methods of using these compounds for the treatment, prevention and management of various diseases and disorders are also encompassed by the invention....

20050282875 - Pyrrolidinium derivatives: i

20050282876 - Inhibitors of impdh enzyme: The present invention relates to a novel class of compounds which are IMPDH inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents...

20050282877 - Method of decreasing inflammation in kidney transplantion using angiotensin receptor blockers: Disclosed is a method of inhibiting production of IFN-Γ in patients having a transplanted organ. The method involves administering to the patient an amount of an angiotensin receptor-blocking compound, the amount being effective to inhibit production of IFN-Γ by T cells. The method can be used to treat inflammation involving...

20050282878 - Process for the purification of fluconazole: The present invention relates to processes for the purification of crude fluconazole including at least a first leaching, a second leaching, and an acid/base treatment and to highly purified fluconazole produced from the processes....

20050282879 - Methods and composition for treatment of migraine and symptoms thereof: Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the...

20050282880 - Novel 1h-indazole compounds: Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by —CO—NH— or...

20050282881 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof: wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized...

20050282882 - Diamines as modulators of chemokine receptor activity: e

20050282883 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA-reductase, as well as...

20050282884 - N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use: The present invention describes carbamic acid ester-derived and valeric acid ester-derived polyfunctional cross-linker molecules, and methods for their synthesis and use. The inclusion of polymeric moieties such as poly(alkylene oxide) in the cross-linkers of the present invention can provide advantageous solubility properties in aqueous environments. Such cross-linkers may be used...

20050282885 - Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050282886 - Lactam tachykinin receptor antagonists: The present invention is directed to certain lactam compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in...

20050282887 - Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders: The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders....

20050282888 - Fungicidal composition: e

20050282889 - Intracorporeal medicaments for photodynamic treatment of disease: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used...

20050282890 - Histone deacetylase inhibitors based on alpha-ketoepoxide compounds: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-ketoepoxide group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase...

20050282891 - Levodopa prodrugs, and compositions and uses thereof: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed....

20050282892 - Pharmaceutical composition useful for treating chronic myeloid leukemia: This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium...

20050282893 - Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors: The invention provides methods and compositions for inhibiting telomerase activity and treatment of telomerase mediated conditions or diseases. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents, surgery, or radiation in the treatment of conditions or diseases mediated by...

20050282894 - Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight: Hydroxycitric acid compositions which comprise approximately 14 to 26% by weight of calcium, and approximately 24 to 40% by weight of potassium or approximately 14 to 24% by weight of sodium, or a mixture thereof, each calculated as a percentage of the total hydroxycitric acid content of the composition, together...

20050282895 - Antimicrobial compositions and methods of use thereof: The present invention is directed to compositions which are useful for reducing and/or preventing bacterial infection/superinfection. The compositions include at least two weak organic acids in an inert carrier vehicle and are delivered at a pH of about 2.5 to 4.5. The weak organic acids are preferably acetic acid, vinegar,...

20050282896 - Methods of cardioprotection using dichloroacetate in combination with an inotrope: The present invention provides compositions and methods for maintaining or improving cardiac function by administering a cardioprotective amount of dichloroacetate (DCA) and an inotropic drug. Also provided are dosage protocols and pharmaceutical compositions for use in these methods....

20050282897 - Methods and compositions for treating diabetes: Methods of treating diabetes in an animal and food compositions useful for treating diabetes are described. In one aspect of the invention, the method includes treating the animal with a therapeutically effective amount of CLA including 9,11-octadecadienoic acid and 10,12-octadecadienoic acid, isomers thereof, esters thereof, salts thereof or mixtures thereof....

20050282898 - Methods for the synthesis of milnacipran and congeners thereof: One aspect of the present invention relates to methods for synthesizing milnacipran or congeners thereof. Another aspect of the present invention relates to asymmetric methods for synthesizing enantiomerically enriched milnacipran or congeners thereof. The present invention also relates to methods for synthesizing intermediates useful in the non-asymmetric or asymmetric methods...

20050282899 - Resorcinol derivatives: The present invention relates to certain resorcinol derivatives and their use as skin lightening agents....

20050282900 - Inhibitors of alpha4 mediated cell adhesion: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof....

20050282901 - Compounds and methods for delivery of prostacyclin analogs: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and...

20050282902 - Abnormal cannabidiols as agents for lowering intraocular pressure: i

20050282903 - Use of treprostinil to treat neuropathic diabetic foot ulcers: The present invention describes novel methods for using 9-deoxy-2′,9-α-methano-3-oxa-4,5,6-trinor-3,7-(1′,3′-interphenylene)-13,14-dihydro-prostaglandin F1 (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of foot ulcers in subjects with diabetic neuropathy. The invention also relates to kits for treatment and/or prevention of foot ulcers, comprising...

20050282904 - Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight: Hydroxycitric acid compositions which comprise approximately 14 to 26% by weight of calcium, and approximately 24 to 40% by weight of potassium or approximately 14 to 24% by weight of sodium, or a mixture thereof, each calculated as a percentage of the total hydroxycitric acid content of the composition, together...

20050282905 - Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient: d

20050282906 - Neural tourniquet: Disclosed is a method of reducing bleed time in a subject by activation of the cholinergic anti-inflammatory pathway in said subject. The cholinergic anti-inflammatory pathway can be activated by direct or indirect stimulation of the vagus nerve. The cholinergic anti-inflammatory pathway can also be activated by administering an effective amount...

20050282907 - Non nucleoside reverse transcriptase inhibitors: s

20050282908 - substituted aminopropoxyaryl derivatives useful as agonists for lxr: The invention relates to a compound of formula (I), wherein all variables are as defined herein, and pharmaceutically acceptable salts or solvates thereof. The compounds of formula (I) are useful as LXR agonists....

20050282909 - Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction: A method is provided for the treatment of a condition mediated by raf kinase, which includes administering a guanylhydrazone to a subject in need thereof. A method is also provided, which includes modulating or inhibiting signal transduction in a c-raf pathway with at least one guanylhydrazone. Another method is provided,...

20050282910 - Methods of application of chemical compounds having therapeutic activities in treating cancers: Methods of application of a class of compounds with a pharmacophore of dibenzocyclooctadiene in the preparation of anticancer medications, and particularly for the preparation of medications for the treatment of P-glycoprotein-mediated multidrug resistant (MDR) cancer and non-P-glycoprotein-mediated MDR cancer, such as multidrug resistant associated protein MRP1-mediated cancer. Methods of increasing...

20050282911 - Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality: The present invention relates to the treatment of major depressive disorder (MDD), and the prevention of suicidality associated therewith, using the uncompetitive NMDA receptor antagonist memantine....

20050282913 - Abnormal cannabidiols as agents for lowering intraocular pressure: e

20050282912 - Abnormal cannabidiols as neuroprotective agents for the eye:

20050277576 - Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs: Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The patient can be a fetus treated in utero or removed from the womb. The progress of...

20050277577 - Compositions and methods for treating diverticular disease: Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease....

20050277578 - Immunity generation: A method for the manufacture of a medicament for immunity generation includes the use of insect tissues, larval forms or derivatives of insects that have been fed on a food containing pathogens....

20050277575 - Therapeutic compositions and methods for treating diseases that involve angiogenesis: According to the present invention, S100A4 protein also known as Mts-1 interferes with the function of Annexin 2 and Annexin2/P11 tetramer by binding to Annexin 2. The present inventors have demonstrated that binding of S100A4 with Annaxin 2 modulates angiogenesis by interfering with Annexin 2 mediated tissue plasminogen activator (tPA)...

20050277579 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an antidiabetic and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of...

20050277580 - Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same: Methods for synthesizing proinsulin polypeptides are described that include a contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide...

20050277581 - Dalbavancin compositions for treatment of bacterial infections: The invention provides methods and compositions for treatment of bacterial infections in adult and pediatric patients. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and skin structure. Dosing regimens include multiple dose administration of dalbavancin,...

20050277582 - Method for inactivating gonadotrophs: Certain toxic compounds (T) such as, for example, compounds based upon diphtheria toxin, ricin toxin, pseudomonas exotoxin, .alpha.-amanitin, pokeweed antiviral protein (PAP), ribosome inhibiting proteins, especially the ribosome inhibiting proteins of barley, wheat, corn, rye, gelonin and abrin, as well as certain cytotoxic chemicals such as, for example, melphalan and...

20050277583 - Histone deacetylase inhibitors and process for producing the same: Compounds represented by formula (1) have strong inhibitory activity that is selective towards HDAC1 and HDAC4. Therefore, the compounds of the present invention are useful as pharmaceutical agents for treating or preventing diseases caused by HDAC1 and HDAC4....

20050277585 - Combinations of immunosupressive agents for the treatment or prevention of graft rejections: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute...

20050277584 - Pharmaceutical compositions comprising cyclosporins: A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an aqueous solution, and wherein no hydrophilic organic solvent is present at a concentration greater than half of that of the cyclosporin is also disclosed herein. A composition...

20050277590 - Analogs of gastric inhibitory polypeptide and their use of treatment of diabetes: The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues...

20050277592 - Beta-peptides: β-peptide regions of polypeptides can serve as structural mimics of α-helices in wild type proteins. Because α-helices of one protein often bind to a target protein in a biological pathway, a polypeptide that contains a helical β-peptide region can be used to disrupt this type of protein-protein binding. As a...

20050277587 - Cd7 as biomarker and therapeutic target for psoriasis: We present information obtained from the occurrence of psoriasis and its related disease pityriasis rubra pilaris (PRP) in a large, five-generation kindred. Using a genome-wide scan and single nucleotide polymorphism (SNP) fine mapping, the psoriasis/PRP locus was mapped to chromosome 17q terminus, a region close to but distinct from the...

20050277588 - Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) and associated uses: Novel compounds are provided that bind to G-CSFR. The novel compounds have a peptide chain approximately 6 to 40 amino acids in length that binds to G-CSFR. The compounds are useful as probes for affinity screening. In addition, the compounds have demonstrated agonist or antagonist activity for the G-CSFR, and...

20050277589 - Linear cationic peptides having antibacterial and/or antifungal properties: A peptide including a first peptide sequence of formula KLAKLAK in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least...

20050277586 - Peptide chemically modified with polyethylene glycol: It is intended to provide a peptide chemically modified with PEG which contains a sequence consisting of 18 amino acids and having a specific structure made up of four planes, i.e., two hydrophobic planes and two hydrophilic planes alternately arranged in an alpha-helix structural model; a complex of the above...

20050277593 - Therapeutic uses of reg protein: Human Reg III and Reg IV proteins are used to treat diseases characterized by neurological damage and inflammation. Such diseases include inflammatory bowel disease, sepsis, multiple sclerosis, amyotrophic lateral sclerosis, adrenoleukodystrophy or adrenomyeloneuropathy, spinal cord injury, Devic's disease. Such treatments lead to prevention or amelioration of disease symptoms, and prolongation...

20050277591 - Use of rpl41 to treat infections and inhibit cancer: The present invention relates to peptides of RPL41 and their use in the treatment of cancer and microbial infections. It is contemplated that modified forms of RPL41, including substitutional variants and mimetics, will be used. Mono- and combination therapies with other cancer treatments are contemplated....

20050277594 - Polypeptide for the treatment of cancer and a method for preparation thereof: This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu and...

20050277595 - Method for treating a patient undergoing chemotherapy: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount angiotensinogen, angiotensin I (AI), AI analogues, AI fragments...

20050277596 - Novel use of peptide compounds for treating amyotrophic lateral sclerosis: The present invention is directed to the use of a class of peptide compounds for treating amyotrophic lateral sclerosis (ALS) and other forms of motoneuron diseases and peripheral neuropathies....

20050277597 - Use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester to treat sunburn and other burns: A method and formulation for treating skin for sunburn and other types of burns is disclosed. The method comprises the topical application of a preparation comprising N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester and its lower alkyl ester derivatives....

20050277598 - Method for improving ventilatory efficiency: A method for improving ventilatory efficiency, comprising the administration of a pentose is disclosed. The most preferred pentose is D-ribose, to be administered in a dosage of from two to ten grams, one to four times daily for at least a week, but most preferably long term....

20050277599 - Pentose derivatives as anti-hyperglycemic drugs: The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport;...

20050277600 - Compositions and methods of use of dimer digallates: The invention relates to compositions, such as pharmaceuticals, foods, food additives, or dietary supplements, containing dimer digallates, and methods of use thereof, for prophylactic or therapeutic treatment of a human or a veterinary animal to treat or prevent NO-responsive health conditions, treat hypertension, cardiovascular disease, coronary artery disease, diabetes, cognitive...

20050277601 - Anticancer biangeloyl saponins: Novel compounds such as compounds designated herein as Xanifolia-Y or -Y3, -Y1, -Y2, -Y8, -Y9 and -Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapindaceae family, such as Xanthoceras sorbifolia, or other natural sources or products. The compounds...

20050277602 - Methods employing agonists of p38 map kinase for the treatment of asthma: Methods for treating asthma using agonists of p38 are disclosed. Also provided are screening methods to identify test compounds which have efficacy for the treatment of asthma....

20050277611 - Cationic cardiolipin analoges and its use thereof: The invention provides cationic cardiolipin compounds, and methods for synthesizing and using them in liposomal formulation, gene transfection, etc. In particular, the invention provides liposomes comprising cationic cardiolipin analog, pharmaceutical compositions comprising cationic cardiolipin analogs, and methods of using such liposomes and compositions, in delivering active pharmaceutical agents to treat...

20050277607 - Compositions and methods for regulating peptidyltransferase activity and uses thereof: The present invention provides compositions and means to identify compositions that increase −1 PRF programmed ribosomal frameshift (−1PRF) efficiencies and/or decrease peptidyltransferase activity in a cell, and thus directly affect viral replication or assembly of viral particles. Compositions identified in accordance with the invention specifically inhibit the interaction between ribosomal...

20050277603 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof: The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such...

20050277604 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed....

20050277609 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed....

20050277610 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that...

20050277612 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a SPHK polypeptide, or fragment thereof, and measuring a compound-SPHK property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including phosphorylated kinase substrate and/or amyloid...

20050277613 - Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases: External Guide Sequence (EGS) are described that target proteins required for generation and modification of the immunoglobulin and T-cell repertoire that are useful for treatment or prevention of inflammatory or related diseases. Formulations suitable for administration of an EGS for treatment of inflammatory or related disease are described. The formulations...

20050277608 - Rna interference mediated inhibtion of vitamin d receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating Vitamin D Receptor (VDR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Vitamin D Receptor...

20050277605 - Superior molecular vaccine based on self-replicating rna, suicidal dna or naked dna vector, that links antigen with polypeptide that promotes antigen presentation: Improved molecular vaccines comprise nucleic acid vectors that encode a fusion polypeptide that includes polypeptide or peptide physically linked to an antigen. The linked polypeptide is one that (a) promotes processing of the expressed fusion polypeptide via the MHC class I pathway and/or (b) promotes development or activity of antigen...

20050277606 - Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1: A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding a polypeptide having an addition, deletion or substitution of one or more amino acids as compared with the amino acid...

20050277614 - Methods for modulating the axonal outgrowth of central nervous system neurons: Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic Brain Injury, cerebral aneurism, spinal cord injury and the like) and methods for inhibiting the axonal outgrowth of central nervous...

20050277615 - Pharmaceutical compositions having anti-inflammatory activity: R3 represents a lower alkyl, lower cycloalkyl, aryl, (ar)alkyl or anilide, said cycloalkyl, aryl and (ar)alkyl may be substituted with one or more of the groups selected from halogen, hydroxyl, hydroxyalkyl; and a pharmaceutically acceptable additive. The composition may be used to threat diseases such as multiple sclerosis, rheumatoid arthritis...

20050277616 - Thymine nucleosides with anti-hepatitis b virus activity: A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-thymine nucleotide, or a phosphate prodrug thereof, optionally in combination therapy with other drugs for the treatment of HBV....

20050277617 - Drugs against articular failure: The object of the present invention is to provide a composition which exerts a higher effect on recovering health from articular disorders than that attained by amino sugars and glycosaminoglycans. The present invention solves the object by providing an agent for treating articular disorders, comprising an amino sugar and trehalose...

20050277618 - Methods: The invention provides a method of identifying a compound useful for treatment of IBD which comprises assaying the compound for its ability to modulate the activity or amount of 3OST4. The assay is selected from measurement of 3OST4 activity using a cell line which expresses 3OST4 or using purified 3OST4...

20050277619 - Novel purine inhibitors of fructose-1,6-bisphosphatase: Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, and their use as fructose 1,6-bisphosphatase inhibitors....

20050277620 - Aryl phosphate derivatives of d4t: Specific aryl phosphate nucleoside derivatives show activity against HIV without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. Examples of aryl phosphate nucleoside derivatives include aryl phosphate derivatives of d4T having one or mote substituents on the aryl group selected from the...

20050277621 - 8-(2-hydroxyphenoxy) octyldiethanolamine and salts thereof for delivery of active agents: The present invention provides 8-(2-hydroxyphenoxy)octyldiethanolamine) and salts thereof, compositions containing the same and one or more active agents, and methods of administering active agents with the same. The delivery agents of the present invention are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other...

20050277622 - 1-calcium phosphate-uracil and method for preparing thereof: The present invention provides a medicament of 1-calcium phosphate-uracil and method for preparing thereof. The method comprises mixing Na2HPO4.12H2O with H3PO4, adding uracil to said phosphoric acid working solution for dissolution, pouring obtained solution into reactor, adding creatine kinase, i.e. CPK, agitating, incubating, and standing at room temperature; filtering, pouring...

20050277623 - Treatment for averting or delaying premature delivery: The present invention relates to a method for averting or delaying premature delivery of mammalian infants. This method includes administering to a pregnant mammalian female an agent which interferes with degradation of cervical and/or fetal membrane connective tissue elements under conditions effective to avert or delay premature delivery of an...

20050277624 - Use of corticosteroids alone or in conjunction with nutritional therapy to reduce stress in animals: The invention provides a method of alleviating the effects of stress in a non-human animal comprising administering a therapeutically effective amount of a corticosteroid, such as dexamethasone, alone or in conjunction with a nutritional supplement, to the animal in need thereof. The corticosteroid can be administered prior to exposure to...

20050277625 - Estriol and estetrol prodrugs: e

20050277626 - Methods and compositions for treatment of nicotine dependence and dementias: In accordance with the present invention, it has been unexpectedly found that the administration of an acetylcholinesterase inhibitor in combination with a tricyclic antidepressant having anti-muscarinic properties provides a highly effective and well tolerated treatment for nicotine dependence and dementias, such as Alzheimer's disease (AD). In one aspect, it is...

20050277627 - Colchinol derivatives as vascular damaging agents: The invention relates to colchinol derivatives of the formula 1: wherein the substituents are as defined in the description or a pharmaceutically-acceptable salt, solvate or pro-drug thereof. The invention also relates to processes for preparing compounds of formula (1), pharmaceutical compositions of compounds of formula (1) and the use of...

20050277628 - Substituted thiophene carboxamides: e

20050277629 - Methods for the treatment of synucleinopathies (lansbury): Methods are provided of treating synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease and Multiple System Atrophy, comprising administering to a synucleinopathic subject one or more farnesyl transferase inhibitor compounds....

20050277630 - Antibacterial agents: Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including...

20050277631 - Vanilloid receptor ligands and their use in treatments: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic...

20050277632 - Beta agonists for the treatment of respiratory diseases: d

20050277633 - Spiro-rifamycin derivatives targeting rna polymerase: Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the current invention relate to a series of novel spiro rifamycin derivatives which have demonstrated potent antimicrobial activity....

20050277634 - Liquid composition for veterinary medicine and process for the preparation and use thereof: A liquid composition comprising: meloxicam, penethamate hydroiodide, and at least one solvent....

20050277635 - Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds: l

20050277636 - Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma: Substituted [1,4]oxazino[2,3-g]indazols for lowering intraocular pressure and treating glaucoma are disclosed....

20050277637 - Arylindenopyridines and related therapeutic and prophylactic methods: b

20050277639 - 2-pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive...

20050277638 - Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor: The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory,...

20050277640 - Pyrimidine derivatives for treatment of hyperproliferative disorders: in which J and Y represent aromatic or heteroaromatic rings; R2, G, G′, and G″ represent substituent groups and R2a represents H or halogen; L represents a linking group; and M represents CH or N. Pharmaceutical compositions containing these compounds, and methods of using these compounds in treatment of hyperproliferative...

20050277641 - 2,4-disubstituted triazine derivatives: the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein −a1=a2−a3=a4—forms a phenyl, pyridinyl, pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl or substituted C1-6alkyl; each...

20050277642 - Pyrimidine kinase inhibitors: As selective inhibitors of inappropriate kinase activities, the compounds of the present invention are useful in the treatment of conditions associated with such activity, including, but not limited to, inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are methods of inhibiting...

20050277643 - Bicycloheteroarylamine compounds as ion channel ligands and uses thereof:

20050277644 - Pyridine analogs as c5a antagonists: The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described...

20050277646 - Vanilloid receptor ligands and their use in treatments: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic...

20050277645 - Sleep inducing compounds and methods relating thereto: including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, L1, L2 and n are as defined herein. Pharmaceutical compositions containing one or more compounds of structure (I), as well as methods relating to the use thereof, including methods for treating insomnia, inducing sleep...

20050277647 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other...

20050277648 - Use of pde iv inhibitors to treat angiogenesis: Selective PDE-IV inhibitors are useful for preventing and treating angiogenic/edema related diseases and disorders....

20050277649 - Aryl sulfonamide compounds and uses related thereto: l

20050277650 - Process for preparing aripirazole hydrate: Aripriprazole hydrate is prepared by dissolving apripiprazole in a hydrous organic solvent at elevated temperature, adding seed crystals of aripiprazole hydrate to the solution, cooling the mixture, and isolating crystals of aripiprazole hydrate....

20050277651 - Preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride): The present invention relates to new and useful processes for the preparation of the anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride....

20050277654 - 4,5-disubstituted-2-aryl pyrimidines: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to...

20050277653 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well...

20050277652 - Novel pyridine derivative and pyrimidine derivative: [R1 represents C1-6 alkyl or the like; R2 and R3 represent hydrogen; R4, R5, R6, and R7 may be the same or different and each represents hydrogen, halogen, C1-6 alkyl or the like; R8 represents hydrogen or the like; R9 represents C1-6 alkyl or the like; V1 represents oxygen or...

20050277655 - Pyrazolopyrimidines: are discussed. These pyrazolopyrimidines are capable of inhibiting the activity of cyclin-dependent kinases, most particularly cyclin-dependent kinase 1 (Cdk1), cyclin-dependent kinase 2 (Cdk2), and cyclin-dependent kinase 4 (Cdk4) and are thus useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also provides pharmaceutical...

20050277656 - Combination comprising docetaxel and a cdk inhibitor: A first aspect of the invention relates to a combination comprising docetaxel, or a derivative or prodrug thereof, and a CDK inhibitor. A second aspect of the invention relates to a pharmaceutical product comprising docetaxel, or a derivative or prodrug thereof, and a CDK inhibitor as a combined preparation for...

20050277657 - Method of protection of biologically active essential oils and pharmaceutical composition for weight control and enhance fat burning in adults, adolescents and children: The subject of this invention is overweight and obesity. The invention relates to use of several natural sources of essential oils such as Cinnamon, Ginger and Turmeric oils. Additional compounds are Citric acid as a fat dissolver and Cocoa extract as an energizer. Especially developed technology is necessary to be...

20050277658 - Protein kinase inhibitors: e

20050277659 - Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists:

20050277660 - Novel tetrahydroquinoline derivatives:

20050277661 - Inhibitors of the hiv integrase enzyme:

20050277662 - Inhibitors of the hiv integrase enzyme: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme....

20050277663 - 3-aryl-3-hydroxy-and 3-aryl-3-oxopropionic acid esters as fungicides: wherein Ar is aryl, Ar1 is a 5 or 6-membered aromatic or heteroaromatic group, Z1 is —OH and Z2 is H; or Z1 and Z2 together are ═O; are described, along with methods of making the same, compositions containing the same, and methods of using the same, particularly as fungicides....

20050277664 - Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid generation: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety for the preparation of a medicament for inhibiting β-amyloid generation....

20050277665 - Arylsulfones and uses related thereto: Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:...

20050277667 - Manufacturing process for methyl phenidate and intermediates thereof: The present invention discloses selective and complete reduction of pyridine ring in a biaryl system comprising ∝-substituted or nonsubstituted benzene ring and relates more specifically, not exclusively, for the manufacture of methylphenidate, which is used for treatment of Attention Deficit Hyperactive Disorder (ADHD) and also acts as central nervous system...

20050277666 - Process of preparing n-ureidoalkyl-piperidines: e

20050277668 - Chemokine receptor binding compounds: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV)....

20050277669 - Preparation of paroxetine involving novel intermediates: Disclosed are processes for preparing novel carbamate intermediates of paroxetine comprising dealkylating N-alkylparoxetine by reaction thereof with a haloalkyl ester of a haloformic acid, in a suitable organic solvent. Also disclosed are processes for preparing paroxetine comprising hydrolyzing the novel carbamate intermediates in a suitable solvent. Paroxetine prepared by the...

20050277671 - Benzimidazolone carboxylic acid derivatives: wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux...

20050277672 - Benzimidazolone carboxylic acid derivatives: wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux...

20050277673 - Benzimidazolone carboxylic acid derivatives: wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux...

20050277670 - Chemokine receptor binding compounds: The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV)....

20050277674 - 4-substituted 1-aminocyclohexane compounds for utilization as orl1-receptor and mu-opiate receptor ligands: e

20050277675 - Nanocarbon solubilizer, method for purifying same, and method for producing high-purity nanocarbon: A water solubilizer for nonocarbons contains a surfactant which can form a spherical micelle vesicle having a diameter of 50-2,000 nm in a water solution or a water-soluble polymer having a weight-average molecular weight of 10,000-50,000,000 as an active constituent. For example, the water solubilizer is used for purification of...

20050277676 - M3muscarinic acetylcholine receptor antagonists: M3 Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided....

20050277677 - Method for treating emesis with ghrelin agonists:

20050277678 - Heterocyclic compounds process for their preparation and pharmceutical compositions containing them and their use in medicine: The present invention describes novel compounds having antiinflamatory activity, process for their preparation and pharmaceutical composition containing them....

20050277679 - Sodium salts of 5-'4-'2-(n-methyl-n-(2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione: A compound 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione sodium salt, or a pharmaceutically acceptable solvate thereof, characterised in that the sodium salt is non-hygroscopic or slightly hygroscapic; a pharmaceutical composition containing such a compound and the use of such a compound in medicine....

20050277680 - Compounds for treatment of cell proliferative diseases: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines....

20050277681 - N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,...

20050277683 - Novel pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use: N-[1-oxo-(optionally 2-aza)-2-alkyl-3-(carboxyl or thiol or hydroxyaminocarbonyl or N-hydroxyformamido)-propyl]-(aryl or heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes, salts or prodrugs thereof have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by PDF inhibitors, such as treatment of bacterial infections....

20050277682 - Therapeutic formulations of desoxyepothilones: Formulations of desoxyepothilones are stable before and after dilution into aqueous media....

20050277684 - Oxidative activation and episulfonium ion-mediated dna alkylation-based anticancer: The present invention relates to TG-25 and/or analogs thereof and their use of TG-25 in the treatment of cancer. TG-25 inhibits the growth of prostate cells by inhibiting DNA synthesis, more particularly by DNA cleavage....

20050277685 - Indoles having anti-diabetic activity: Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2...

20050277686 - Benzimidazole compounds for regulating ige: This invention relates to a family of phenylbenzimidazole analogs, which are inhibitors of the IgE response to allergens. These compounds are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic....

20050277687 - Combination of selected analgesics and cox-ii inhibitors: Combinations of certain analgesics with certain COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and to the use thereof in methods of treatment, in particular for the treatment of pain....

20050277688 - Crystalline form of a substituted pyrrolidine compound: The invention provides a crystalline naphthalene-1,5-disulfonic acid salt of 2-[(S)-1-(8-methylaminooctyl)pyrrolidin-3-yl]-2,2-diphenylacetamide or a solvate thereof. This invention also provides pharmaceutical compositions comprising the salt or prepared using the salt; processes and intermediates for preparing the salt; and methods of using the salt to treat a pulmonary disorder....

20050277689 - Carvedilol salts, corresponding compositions, methods of delivery and/or treatment: The present invention relates to a salt of carvedilol and/or corresponding solvates thereof, compositions containing such carvedilol and/or corresponding solvates thereof, and/or methods of using the aforementioned compound(s) in the treatment of certain disease states in mammals, in particular man. The present invention further relates to carvedilol phosphate salts, and/or...

20050277690 - Small molecules for treatment of hypercholesterolemia and related diseases: The present invention provides compositions adapted to enhance reverse cholesterol transport in mammals. The compositions are suitable for oral delivery and useful in the treatment and/or prevention of hypercholesterolemia, atherosclerosis and associated cardiovascular diseases....

20050277691 - Pravastatin pharmaceutical formulations and methods of their use: The present invention relates to formulations comprising a therapeutically effective amount of pravastatin, or a pharmaceutically acceptable salt thereof, and methods of their use. The present formulations and methods are designed to release little or no pravastatin in the stomach but release a therapeutic amount of pravastatin in the small...

20050277692 - Process for preparing difluorobenzo-1,3-dioxole-5-carboxylic acid derivatives: The invention relates to a process for preparing difluorobenzo-1,3-dioxole-5-carboxylic acid and derivatives thereof, and to the use thereof for preparing medicaments and crop protection agents....

20050277693 - Basic salts and monohydrates of certain alpha, beta-propionic acid derivative: The invention provides novel salts of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid, including Arginine salt of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid monohydrate, Arginine salt of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl) propylamino} phenyl] propionic acid, and (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl)propylamino} phenyl] propionic acid monohydrate. Various aspects and embodiments are included. Compositions containing novel salts of (S)-2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl) propylamino}phenyl] propionic acid are also...

20050277694 - Topical compositions and methods for epithelial-related conditions: The present invention relates to pharmaceutical, cosmetic and cosmeceutical topical compositions containing polyisoprenyl-protein inhibitor compounds and methods useful in the promotion of healthy epithelium and the treatment of epithelial-related conditions...

20050277695 - Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes: Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of...

20050277696 - Novel use of cytotoxic drugs for treatment and prophylasxis of aging diseases by reversing the loss of elasticity of epithelial cells due to aging: A method for treatment of age-related symptoms of epithelial tissues that includes the administration of an agent that disrupts F-actin polymerization in an amount effective to reduce rigidity in epithelial cells....

20050277697 - Method for treatment of the common cold, flu, and virus symptoms: This invention relates to the treatment of a person exhibiting the effects of a flu-like or viral infection. The method includes treating the person with an amphetamine, amphetamine derivative, or a salt thereof in an amount effective to alleviate the adverse symptoms resulting from the flu-like or viral infection....

20050277698 - Memantine delivery to the back of the eye: Disclosed herein are aqueous solutions comprising a neuroprotective amine related to adamantane and a polyanionic polymer. Also disclosed herein are methods of treating glaucoma and methods of treating a disease or a condition wherein migration or proliferation of retinal pigment epithelium or glial cells causes or contributes to the cause...

20050277699 - Method of decreasing sebum production and pore size: Cosmetic compositions and methods of decreasing sebum production and/or pore size by contacting skin with a hair growth inhibitor, including polyamine derivatives and/or analogs; DFMO, N-acetyl cysteines; neutralized salts of a non-hydroxy C2-C40 dicarboxylic acids, preferably malonate salts; and mixtures thereof. Additional sebum and/or pore size reducing agents, such as...

20050277700 - Non-halogenated hydroxyalkyl-substituted phenol compounds, antimicrobial compositions containing the same, and methods of using the same: A antimicrobial compound, compositions containing the same, and method of using the same for reducing the presence of microorganism on a substrate or in a fluid environment comprising an antimicrobial effective carrier and at least one antimicrobial compounds including non-halogenated hydroxyalkyl-substituted phenol compounds....

20050272637 - Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors: The binding interactions between herstatin, or the intron 8-encoded receptor binding domain (RBD Int8) thereof, and several receptors were analyzed. According to aspects of the present invention, herstatin and the intron 8-encoded domain bind with high affinity (e.g., nM concentrations) to all four of the ErbB receptors: EGFR (HER-1, erbB-1);...

20050272638 - Compounds and compositions for delivering active agents: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well....

20050272633 - Derivatives of the nf-kappab inducing enzyme, their preparation and use: This invention relates to the use of NIK and related molecules for the modulation of signal activities controlled by cytokines, and some new such molecules....

20050272636 - Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-gamma: The invention provides compositions and methods for diagnosing and treating reproductive disorders. The invention also provides methods for diagnosing reproductive disorders by detecting the presence of IFN-γ in the semen of a prospective father, which is indicative of the presence of a reproductive disorder. In particular, the invention provides a...

20050272635 - Use of corticotroph-derivced glycoprotein hormone to treat liver steatosis: The use of corticotrph-derived glycoprotein hormone to treatment liver steatosis, liver steatohepatitis, and cirrhosis of the liver, as well as other abnormalities in hepatic function that are related to obesity....

20050272634 - Use of erythropoietin: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical...

20050272640 - Method and apparatus for glucose control and insulin dosing for diabetics: A computer implemented method and associated apparatus for the combined control of insulin bolus dosing and basal delivery for the goal of achieving normal glycemic response to meals, exercise, stressors, and other perturbations to blood glucose levels. A run-to-run algorithm is used to monitor blood glucose levels and adjust insulin...

20050272639 - Polymorphs of sodium 4-{4-chloro-2-hydroxybenzoyl) amino} butanoate: The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target....

20050272641 - Therapeutic agents for diabetes: A pharmaceutical composition for preventing and/or treating diabetes, diabetic complication, hyperinsulinemia, disorders of glucose metabolism or obesity, comprising a combination of the following compound, analogues or pharmaceutically acceptable salts thereof with a hypoglycemic agent....

20050272642 - Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog: Methods and compositions for protecting and treating a muscarinic receptor in a subject in need thereof from dysfunction not resulting from oxidative stress, toxic actions of metals or metal ions, or infectious agents by administering a pyrophosphate analog....

20050272643 - Removal of serum albumin from human serum or plasma: A method of removing serum albumin from blood serum or plasma includes contacting the blood serum or plasma with a sugar-binding protein such as a lectin (e.g., Concanavalin A or wheat germ agglutinin) immobilized on an insoluble support such as a porous bead (e.g., agarose). The method may be practiced...

20050272644 - Method for increasing therapeutic gain in radiotherapy and chemotherapy: The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable...

20050272645 - Retrocyclins: antiviral and antimicrobial peptides: Retrocyclin peptides are small antimicrobial agents with potent activity against bacteria and viruses. The peptides are nonhemolytic, and exhibit minimal in vitro cytotoxicity. A pharmaceutical composition comprising retrocyclin as an active agent is administered therapeutically to a patient suffering from a bacterial and/or viral infection, or to an individual facing...

20050272646 - Streptogramin antibiotics: Disclosed is a cyclic peptide antibiotic in which an enzyme-sensitive bond is replaced by an enzyme-resistant bond....

20050272647 - Arthrodial cartilage extracellular matrix degradation inhibitor: An agent for inhibiting articular cartilage extracellular matrix degradation of the present invention, comprising a histone deacetylase-inhibiting compound as an active ingredient, is effective for the prevention and treatment of diseases and pathological conditions involving the degradation and degeneration of the articular cartilage extracellular matrix, in particular, arthrosteitis, rheumatic arthritis,...

20050272653 - Bmp-3 propeptides and related methods: The present invention provides compositions and methods for promoting bone growth. The present invention also provides methods of screening compounds that modulate BMP-3A or BMP-3B activity. The compositions and methods provided herein are useful in modulating bone growth....

20050272649 - Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure: The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor...

20050272648 - Ghrelin analogs: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof....

20050272657 - Human growth hormone aqueous formulation: A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations....

20050272650 - Materials and methods for treatment of inflammatory and cell proliferation disorders: The present invention pertains to methods for treatment of inflammatory and cell proliferation disorders, such as cancer, by administering an agent that reduces atrial natriuretic peptide receptor-A (NPR-A) activity. In one aspect, the invention concerns a method for treatment of inflammatory and cell proliferation disorders, such as cancer, by administration...

20050272656 - Method for enhancing proliferation or differentiation of a cell using ob protein: Uses for WSX ligands in hematopoiesis are disclosed. In particular, in vitro and in vivo methods for stimulating hematopoiesis (e.g., myelopoiesis, erythropoiesis and especially, lymphopoiesis) using a WSX ligand (e.g., anti-WSX receptor agonist antibodies or OB protein), and optionally another cytokine, are described....

20050272651 - Methods for treating breast cancer using nrif3 related molecules: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to...

20050272655 - Methods of using il-1 antagonists to treat autoinflammatory disease: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is...

20050272654 - Nf-kappab activation inhibitors, and their pharmaceutical uses: Compounds inhibiting the activation of the nuclear factor κB (NF-κB) are used for the preparation of medications adapted for the treatment of malignant hemopathies and solid tumors, and for the prevention of the appearance or the treatment, of phenomena of resistance to cytotoxic molecules used in the scope of treatment...

20050272652 - Peptide analogues of gip for treatment of diabetes, insulin resistance and obesity: The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and/or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and...

20050272658 - Applications of peptides derived from the cytoplasmic domain of amyloid precursor protein (app): The invention concerns novel uses of peptides derived from the cytoplasmic domain of the amyloid protein precursor (APP); said peptides are in particular sequences including the membrane domain juxtaposed to the cytoplasmic domain of the amyloid protein precursor (APP) (one-letter code), selected in the group consisting of the sequences Y1KQYTSIHHGY0...

20050272659 - Helical peptidomimetics with enhanced activity: Helical peptidomimetic compounds as inhibitors of beta-amyloid production are provided. These inhibitors have sequences with lengths from 11 to 16 amino acids, inclusive. These inhibitors potently inhibit intramembrane proteases, notably aspartyl secretases involved in the enzymatic cleavage of amyloid precursor protein (APP) to yield amyloid-β-peptide. Methods are provided for making...

20050272660 - Polypeptide derivatives of parathyroid hormone (pth): Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods...

20050272661 - Neo-tryptophan: The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and...

20050272662 - Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals: The present invention provides a mixture of self-assembling peptide-amphiphiles with complementary charges whose design and function is patterned after proteins having biological functions. The oppositely charged peptide amphiphiles may be self-assembled by combining them in a charge equivalent ratio. Variations of structural peptide sequences in the oppositely charged peptide-amphiphiles enable...

20050272664 - Methods for inhibiting angiogenesis and or lymphangiogenesis: Proprotein convertase inhibitor has been found to block proteolytic processing and activation of VEGF-C and VEGF-D and inhibit angiogenesis and/or lymphangiogenesis. Method and composition are disclosed for inhibiting angiogenesis and/or lymphangiogenesis, and for treating conditions associated with excessive angiogenesis, such as tumors and/or retinopathies, as well as conditions associated with...

20050272663 - Novel substituted prolines as inhibitors of hepatitis c virus ns3 serine protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease....

20050272665 - Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters: e

20050272667 - Analogs and derivatives of (s,s,r)-(-)-actinonin and uses therefor: where R1 is hydrogen, C(O)R6 or R1 in combination with N is 2-oxomorpholine, R2 is hydrogen, methyl, CH2CH(CH3)2, (CH2)2CH3, CH(CH3)2, (CH2)3CH3, (CH2)4NH2, (CH2)3CO2H, phenyl, 3,4-dichlorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH2-(N-Boc-4-piperidine), 4-tetrahydropyran, CH2-4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl, R3 is R2 or C3-8alkyl, R4 is C1-3alkyl, R5 is NH2,...

20050272668 - Anti-inflammatory compositions and methods: The disclosed invention includes pharmaceutical compositions and methods for treating inflammatory conditions, particularly those that are characterized by increased binding of alpha-9 integrin to one or more of its ligands. Also disclosed are methods for selecting compounds for use in such compositions and methods....

20050272666 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds: Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical...

20050272669 - Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB...

20050272670 - Synthesis and use of glycodendrimer reagents: The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine n a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also a method of producing the chemically modified mutant...

20050272671 - Compositions comprising hepoxilin analogs and their use in the treatment of cancer: e

20050272672 - Ketolide anti-infective compounds:

20050272673 - Pharmaceutical combination and method for treatment of reactive arthritis or bursitis: A method for treatment for conditions in human beings associated with either or both reactive arthritis or bursitis comprising administering a combination of a member from each of the following groups of medications: (1) synthetic purine nucleoside analog antiviral drugs, (2) antibiotic drugs, and (3) imidazole drugs. Alternate embodiments of...

20050272674 - Preparation method of valienamine from acarbose and/or acarbose derivatives using trifluoroacetic acid: The present invention provides a preparation method of valienamine from acarbose or acarbose derivatives using organic acid TFA (trifluoroacetic acid). By using the method of the present invention, valienamine, the core precursor of voglibose which is a strong retardant of α-glucosidase and which is used for the cure of diabetes,...

20050272675 - Methods for isolating crystalline form i of 5-azacytidine: e

20050272676 - Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase: The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B...

20050272683 - Antisense oligonucleotides against thymidylate synthase: Antisene oligonucleotides targeted to sequences in thymidylate synthase (TS) mRNA. In particular the invention relates to antisense oligonucleotides targeted to sequences in the 3′ end of TS mRNA, which are both cytostatic on their own when administered to human tumour cell lines, and which also enhance the toxicity of anticancer...

20050272678 - Bmp-6 estrogen responsive element and methods of use thereof: This invention is directed to a BMP-6 ERE nucleic acid sequence, vectors, cells and compositions comprising same. This invention also provides methods for identification of estrogen agonists, antagonists and therapeutic applications of same. This invention also provides methods of treating conditions, which are associated with estrogen insufficiency or with lack...

20050272684 - Breast cancer resistance protein (bcrp) and the dna which encodes it: The Breast Cancer Resistance Protein is described, as well as the cDNA encoding said protein. This protein has been found to confer resistance to cancer chemotherapeutic drugs....

20050272677 - Delivery of a substance to a pre-determined site: The invention is directed to delivery vehicles for delivering a substance of interest to a predetermined site. The delivery vehicle includes a substance and means for inducing availability of at least one compartment of the delivery vehicle toward the exterior, thus, allowing access of the substance to the exterior of...

20050272685 - Intraductal treatment targeting methylated promoters in breast cancer: The invention provides compositions for targeting methylated promoters in breast cancer and pre-cancer patients. The invention also provides methods for intraductal treatment of breast cancer and pre-cancer patients by delivering intraductally an agent that targets methylated promosters of silenced genes....

20050272679 - Modified polynucleotides and uses thereof: Provided is a polynucleotide comprising mRNA, rRNA or viral RNA, comprising ribose rings that are covalently modified at the 2′-OH position. Further provided are methods for producing a double-stranded oligo- or polynucleotide from a template comprising an oligo- or polyribonucleotide, a proportion of the ribose rings of which are covalently...

20050272680 - Modulation of diacylglycerol acyltransferase 2 expression: Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression...

20050272681 - Ribosome structure and protein synthesis inhibitors: The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and...

20050272682 - Sirna targeting pi3k signal transduction pathway and sirna-based therapy: Small interfering RNAs (siRNAs) are provided specifically targeting a PI3K signal transduction pathway. Also provided are various siRNA-based therapies....

20050272686 - Nucleotide based medicament and method of use for treatment of conditions in humans: A dietary supplement comprising nucleotides in a yeast carrier alone or in combination with antioxidants, amino acids and vitamins is provided that is beneficially used for the treatment of irritable bowel syndrome, chronic diarrhea and cold or flu symptoms as well as for modulating serum HDL and LDL cholesterol levels....

20050272687 - Stable s-adenosyl-l-methionine: Stable conjugates of S-adenosyl-1-methionine, methods for their synthesis and methods for their uses are described. The conjugates according to the invention are very stable and are valuable for use as active constituents in pharmaceutical compositions....

20050272688 - Combined treatment with gemcitabine and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and gemcitabine combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20050272689 - Methods, compositions, and kits for organ protection during systemic anticancer therapy: Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents....

20050272690 - Compositions and methods for sleep regulation: Compositions and methods for the regulation of sleep and circadian rhythms are provided. The compositions are nutritional supplements containing melatonin and one or more vitamins that enhance the effectiveness of melatonin. Preferred vitamins include folic acid, riboflavin (vitamin B2), cobalamin (vitamin B12) or pyridoxine (vitamin B6). The compositions beneficially and...

20050272691 - Treatment of dermatological conditions: The present invention provides a method for treating dermatological conditions, such as psoriasis, dermatitis, and dandruff. Said conditions are treated by administering to a person a vitamin supplement composition comprising folic acid, vitamin B12 and/or vitamin B6. The vitamin supplement composition may also be essentially free of antioxidants...

20050272693 - Prophylactic and therapeutic treatment of infectious and other diseases with mono-and disaccharide-based compounds: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants....

20050272692 - Sucrose ester compounds useful as fungicides: t

20050272694 - Composition containing beta-glucan and constipation-relieving drug, immunopotentiatior, and skin moistening agent using the composition: The present invention provides a composition containing β-glucan in which the physiologically active effects of β-1,3-1,6-glucan contained in a cultured composition of a bacterium belonging to the genus Aureobasidium sp. are further enhanced, and a constipation-relieving drug, preparation an immunopotentiator, and a skin moistening agent using the composition. A composition...

20050272695 - Fast dissolving dried hyaluronic acid product: The present invention relates to atomized products comprising hyaluronic acid or a salt thereof, which product has a high solubility in an aqueous solvent, various compositions and articles comprising the product or compositions of the invention, methods of producing the product of the invention, and uses thereof....

20050272696 - Methods of selectively treating diseases with specific glycosaminoglycan polymers: The present invention demonstrates that defined, specific GAG molecules have discerned differential effects, and that different types of cancers are prevented from proliferating and/or killed by oligosaccharides of different sizes; one size sugar does not treat all cancers effectively. Likewise, certain size GAGs have more potent angiogenic properties; thus, mixtures...

20050272697 - Composition and method for treating post-surgical pain: A composition for reducing pain at a surgical wound site or trauma site comprising oxidized regenerated cellulose and a non-steroidal anti-inflammatory drug or pharmaceutically acceptable salt or ester thereof, where the non-steroidal anti-inflammatory drug is an acid having a secondary amine group; and a method of reducing localized pain at...

20050272699 - Acrylonitrile derivatives for inflammation and immune-related uses: c

20050272698 - Liquid stable composition of oxazaphosphorine with mesna: A low toxicity, stable oxazaphosphorine containing compositions with mesna for parenteral administration has been described. The process essentially requires addition of an oxazaphosphorine antineoplastic to the aqueous solution of an etherified β-cyclodextrin followed by addition of mesna as such or as an aqueous solution containing optionally, an etherified β-cyclodextrin. Preferably,...

20050272701 - Pharmaceutical composition: The present invention relates to a pharmaceutical composition containing a cycloalkene compound a salt thereof or a prodrug thereof, and a nonionic surfactant and/or a cyclodextrin derivative readily soluble in water, and a method for improving solubility, stability or coloring property of the compound, a salt thereof or a prodrug...

20050272700 - Topical treatment and prevention of human papilloma virus (hpv) infection: The present invention contemplates a topical pharmaceutical composition that comprises a medium containing an anti-viral-effective amount of the dietary indole or derivative thereof admixed with a dietary indole compound-complexing amount of a hydroxypropyl-β-cyclodextrin dissolved or dispersed therein. Another embodiment utilizes sorbitol to stabilize the indole. The indole compound remains stable...

20050272703 - Anti-tumor agents: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in...

20050272704 - Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding: Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are biphenyls and related compounds....

20050272702 - Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls: A convenient preparation of boron-containing compounds, borate salts, pyrrolecarbonitrile boron-containing compounds, N-substituted-pyrrole-2-carbonitrile boron-containing compounds, and derivatives thereof is provided. The present invention also provides for the use of these boron-containing compounds and derivatives thereof in coupling reactions to provide bi-aryl compounds....

20050272705 - Method of adminstering bisphosphonates: Bisphosphonates, in particular more potent N-bisphosphonates such as zoledronic acid and derivatives, can be used with satisfactory results for treatment of RA by intermittent administration, wherein the periods between bisphosphonate administrations are from about 2 months up to about 4 months, e.g. once every 3 months....

20050272706 - Process for the preparation of sodium fosphenytoin: Phosphoric acid diester 2,5-dioxo-4,4-diphenylimidazolidin-1-ylmethyl esters, both of whose ester groups can be selectively cleaved, are obtained by converting 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione to an alkylsulfonate or arylsulfonate and reacting this with a phosphoric acid diester whose ester groups can be selectively cleaved from the reaction product. The two ester groups can be selectively...

20050272707 - Method for preventing or reducing secondary fractures after hip fracture: Use of a bisphosphonate in the preparation of a medicament for the treatment of osteoporosis post hip fracture to prevent or reduce subsequent osteoporotic skeletal fractures in a patient in need of such treatment, and particularly to a patient who has undergone recent repair of the hip fracture and corresponding...

20050272708 - Akt inhibitors, pharmaceutical compositions, and uses thereof: Disclosed are inhibitors of the serine/threonine kinase Akt, pharmaceutical compositions comprising such inhibitors, and a method of preventing or treating a disease or condition in an animal by the use of such inhibitors. The Akt inhibitors have the formula (I) wherein X and Y are independently selected from the group...

20050272709 - Immugenic compositions and diagnostic and therapeutic uses thereof: Pharmaceutical compositions and compounds are provided. The compounds of the invention deomonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical...

20050272710 - Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration: This invention is directed to methods for providing sustained systemic concentrations of therapeutic or prophylactic agents such as GABA analogs following oral administration to animals. This invention is also directed to compounds and pharmaceutical compositions that are used in such methods....

20050272711 - Substance for lowering high cholesterol level in serum and methods for preparing and using the same: The invention relates to a substance which lowers LDL cholesterol levels in serum and which is fat soluble β-sitostanol fatty acid ester, and to a method for preparing and using the same. The substance can be taken orally as a food additive, food substitute or supplement. A daily consumption of...

20050272712 - Compositions and methods for treatment of premenstrual dysphoric disorder: The present invention relates to a method for treating premenstrual dysphoric disorder through administration of at least one progestin and at least one estrogen to a female subject....

20050272713 - Supramolecular complexes as photoactivated dna cleavage agents: The invention provides supramolecular metal complexes as DNA cleaving agents. In the complexes, charge is transferred from one light absorbing metal (e.g. Ru or Os) to an electron accepting metal (e.g. Rh) via a bridging π-acceptor ligand. A bioactive metal-to-metal charge transfer state capable of cleaving DNA is thus generated....

20050272714 - Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity: A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an...

20050272716 - Use of parthenolide derivatives as antileukemic and cytotoxic agents: Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—,...

20050272715 - Optically active dihydropyridine derivative: The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5-isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases....

20050272717 - Treatment of aromatase inhibitor therapy-related osteoporosis: This invention relates to the use bazedoxifene (1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol) in the treatment or inhibition of osteoporosis and osteopenia related to aromatase inhibitor therapy....

20050272718 - Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases....

20050272719 - Method for inhibiting detrusor muscle overactivity: The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis. The method comprises administering to...

20050272720 - Process for making olanzapine form i: Heating a solid, preferably crystalline, olanzapine acetate can produce olanzapine Form I in high purity, free of other olanzapine forms and in good yields. The olanzapine acetate can also be used to purify raw or technical grade olanzapine and to serve as an intermediary to other forms of olanzapine base....

20050272721 - Stable salts of olanzapine: Several salts of olanzapine, including olanzapine malonate, olanzapine glycolate, olanzapine maleate, and olanzapine benzoate, have been found to have favorable solid state characteristics....

20050272723 - Methods and compositions for treating diseases and conditions associated with mitochondrial function: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, mitochondrial F1F0 ATP hydrolase...

20050272722 - Methods for the treatment of synucleinopathies: Methods are provided of treating synucleinopathies, such as Parkinson's Disease, Diffuse Lewy Body Disease and Multiple System Atrophy, comprising administering to a synucleinopathic subject a farnesyl transferase inhibitor compound....

20050272724 - Spin trapping pharmaceutical compositions and methods for use thereof: Spin trapping compositions in general have now been discovered to be effective in treating a variety of disorders, including disorders such as those arising from ischemia, infection, inflammation, exposure to radiation or cytotoxic compounds, not just of the central and peripheral nervous systems but of peripheral organ disease having a...

20050272725 - Enzymatic process for deacetylation of a phenoxy-alkynyl acetate to the corresponding alcohol: i

20050272726 - Novel medicaments for the treatment of respiratory diseases:

20050272727 - Leptomycin compounds:

20050272728 - Bicyclic-substituted amines having cyclic-substituted monocyclic substituents: wherein R1 or R2 is an aromatic or non-aromatic ring directly joined or joined by a linker, as represented by L2 and L3, to a heteroaromatic core, and X, X′, Y, Y′, Z, Z′, R1, R2, R3, R3a, R3b, R4, R5, L, L2, and L3 are as defined herein, are...

20050272729 - Cytotoxic agents comprising taxanes and their therapeutic use: A cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for killing selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a linking group, and (B) a pharmaceutically acceptable carrier, diluent...

20050272730 - Thienopyridazines as ikk inhibitors: c

20050272731 - Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for production and the use: The invention relates to new protected 3,5-dihydroxy-2,2-dimethyl-valeroarnides for the synthesis of edothilones and derivatives and process for the production and the use of the new compounds for the production of epothilones or epothilone derivatives....

20050272732 - 5-ethyl-imidazo (5,1-f) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors: The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases....

20050272733 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto: wherein A, R1, R2, R3a, R3b, R4, R5, R6, and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for...

20050272734 - Benzothiazole antiviral agents: The invention encompasses a series of benzothiazole compounds which inhibit HIV entry and are useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for using these compounds....

20050272735 - 1h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands...

20050272737 - Combined treatment with irinotecan and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and irinotecan combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20050272738 - Combined treatment with oxaliplatin and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and oxaliplatin combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20050272736 - Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands: wherein R1 or R2 is a tricyclic or bicyclic ring, each of which contains at least two heteroatoms, and R1, R2, R3, R3a, R3b, R4, R5, L, X, X′, Y, Y′, Z, and Z′ are as defined herein, are useful in treating conditions or disorders prevented by or ameliorated by...

20050272739 - N-aryl diazaspiracyclic compounds and methods of preparation and use thereof: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds and compositions...

20050272740 - Benzimidazole derivatives: m

20050272741 - Novel methods of treatment for fontan patients with protein losing enteropathy: Methods for treating Fontan patients with protein losing enteropathy is provided....

20050272742 - Process for making aripiprazole particles: A method of preparation of crystalline aripiprazole monohydrate includes the use of solution enhanced dispersion by supercritical fluid. Specifically, water is introduced to a stream of supercritical fluid which is then allowed to mix with a stream including a mixture including aripiprazole and a solvent. The mixing results in the...

20050272744 - N-sulfonylcarboximidamide apoptosis promoters: m

20050272743 - Prostaglandin derivatives: Prostaglandin nitroderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension....

20050272745 - Novel piperidine and piperazine derivatives: The invention provides piperidine and piperazine derivatives of general formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy....

20050272746 - Inactive isomer compositions for use as drug-resistance-reversal agents and in prophylactic treatment: A method of using inactive isomer compositions as drug-resistance-reversal agents and in prophylactic treatment includes the steps of selecting an antihistaminically-inactive isomer of a preselected antihistamine, and making stereoselective use of the antihistaminically-inactive isomer for a clinical purposes. The making step includes choosing one of the following clinical purposes for...

20050272747 - Preparation of triazoles by organometallic addition to ketones and intermediates therefor: wherein R1 and “Het” are as previously defined for a compound of the formula (I) and X is chloro, bromo or iodo, in the presence of zinc, iodine and/or a Lewis acid and an aprotic organic solvent: said process being optionally followed by conversion of the compound of the formula...

20050272748 - 2-mercapto-substituted triazolopyrimidines, methods for the production thereof, the use of the same for controlling patogenic fungi, and agents containing said compounds: e

20050272749 - 5-alkyl-7-aminotriazolopyrimidines, methods and intermediary product necessary for the production thereof, agents containing said compounds and the use thereof for fighting against harmful mushrooms:

20050272750 - Novel compound: A compound of formula (I) and pharmaceutically acceptable salts or solvates thereof for use in therapy....

20050272751 - 4-substituted piperidine derivatives: wherein each of R1a, R1b, R1c, R1d, R1e, R1f, R1g, R1h, R2, R2A, R3, R4, A, X, a, x and n is as defined in the specification. Substituted piperidine compounds of structure I may permeate or penetrate across a nerve cell membrane into the interior of a nerve cell, may...

20050272752 - Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same: This invention relates to methods of making sesquisuccinate complexes of E-2-Methoxy-N-(3{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide....

20050272753 - Diaminopyrimidinecarboxa mide derivative: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided. A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with...

20050272754 - Polymorphic forms of rifaximin, processes for their production and uses thereof: The present invention relates to rifaximin polymorphic forms α, β and γ, the processes for their preparation and the use thereof in the manufacture of medicinal preparations for the oral or topical route....

20050272755 - Method for treating abnormal cell growth: The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b)...

20050272758 - Antineoplastic combinations of cci-779 and rituximab: This invention provides the use of a combination of CCI-779 and rituximab in the treatment of non-Hodgkin's lymphoma....

20050272759 - Carboline derivatives useful in the inhibition of angiogenesis: In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy...

20050272757 - Process to prepare camptothecin derivatives and novel intermediate and compounds thereof: New processes are disclosed for the preparation of camptothecin derivatives, such as, irinotecan and topotecan, as well as new intermediates and compounds related thereof....

20050272756 - Pyridopyrrolizine and pyridoindolizine derivatives: Pyridopyrrolizine and pyridoindolizine derivatives are prostaglandin receptor antagonists useful for the treatment of prostaglandin-mediated diseases such as allergic rhinitis, nasal congestion and asthma....

20050272760 - Use of pyridoindolone derivatives for the preparation of medicinal products: r

20050272761 - 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders: The present invention relates to novel 3,5-substituted 7-azaindole compounds of formula (I), their use in the inhibition of c-Jun N-terminal kinases, their use in medecine and particularly in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation. The invention also provides processes for manufacture of said compounds,...

20050272762 - Thienopyridines as ikk inhibitors: e

20050272763 - Substituted furo[2,3-b]pyridine derivatives: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,...

20050272765 - Dipeptidyl peptidase inhibitors: v

20050272764 - Imidazopyridine compound: wherein R1 represents a C1-C6 alkyl group or C2-C6 alkynyl group which may be substituted, or a phenyl group which may be substituted, R2 represents a hydrogen atom or a C1-C6 alkyl group, R3 represents methyl or ethyl group, R4 represents a C1-C6 alkyl group, R5 represents a hydrogen atom,...

20050272766 - 1-glyoxylamide indolizines for treating lung and ovarian cancer: e

20050272767 - Method for treating myolytic disease and method for screening antimyolytic agent: An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase...

20050272768 - Process for preparation of amorphous form of a drug: Provided is a process for preparation of amorphous form of an active pharmaceutical ingredient....

20050272769 - Diamine beta2 adrenergic receptor agonists: The invention provides novel β2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds....

20050272770 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well...

20050272772 - Pharmaceutical compositions for the treatment of pruritus: Composition comprising: a carrier; a first active ingredient comprising capsaicin, a capsaicin analog, another vanilloid receptor agonist or mixtures thereof; and at least one second active ingredient that functions as a topical anesthetic to cause localized numbness to induced skin irritation. Technique for treating the symptoms of pruritus comprising the...

20050272771 - Process for production of piperidine derivatives: R4 is an alkyl or aryl moiety; A, B, and D are the substituents of their rings, each of which may be different or the same, and are selected from the group consisting of hydrogen, halogens, alkyl, hydroxy, alkoxy, and other substituents....

20050272774 - Substituted cyclohexane derivatives: wherein A1, A2, A3, A4, A5, A6, A7, A8 , A9, A10, U, V, W, m, n and p-are as indicated in the specification, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia and...

20050272773 - Use of r (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-flurophenyl)-ethyl]-4- piperidinemethanol for the treatment of sleep disorders and process for making pharmaceutical composition: A process for making a pharmaceutical composition for treating a variety of sleep disorders comprising an effective amount of R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof is disclosed and claimed....

20050272775 - Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof: The present invention discloses a novel, stable polymorph of 1-benzyl-4[(5,6-dimethoxy-1-indanone)-2-yl]methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and its polymorph Form (VI)....

20050272776 - Compositions containing opioid antagonist: Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having...

20050272777 - Vanilloid receptor ligands and their use in treatments: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic...

20050272778 - Inhibitors of proteins that bind phosphorylated molecules: The present invention provides compounds that can modulate the activity of a target protein, such as a phosphatase, that selectively binds phosphorylated peptides or proteins. The present compounds can be useful in treating diseases or disorders, including, for example, diabetes and obesity, that are connected directly or indirectly to the...

20050272779 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists: e

20050272780 - Small molecule inhibitors of rotamase enzyme activity: This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity....

20050272781 - Methods for the synthesis of pyridoxamine: i

20050272782 - Pharmaceutical preparations containing substituted 2,5-diaminomethyl-1h-pyrroles:

20050272783 - Amino acids with affinity for the alpha2delta-protein: This invention relates to certain β-amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric pain and other disorders....

20050272784 - Inhibitors of bacterial type iii protein secretion systems: In accordance with the present invention, compounds that inhibit Type III protein secretion have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein secretion and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial...

20050272785 - Biphenyl carboxamides:

20050272786 - Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents:

20050272787 - Process for preparing crystalline form a of valdecoxib: Valdecoxib Form A is prepared by a process comprising adding aqueous ammonia to a solution of 4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl chloride in a halogenated hydrocarbon or water....

20050272788 - Indoles having anti-diabetic activity: Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2...

20050272789 - Triazole-derived kinase inhibitors and uses thereof: d

20050272790 - Galenic formulations of organic compounds: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active incredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form....

20050272791 - Benzimidazoles and benzothiazoles as inhibitors of map kinase: The present invention provides kinase inhibitors of Formula I: wherein W represents inter alia imidazol, oxazol, pyrazol, thiazol as triazol, which are substituted by phenyl or thienyl. The disclosed compounds inhibit p-38 kinase and are useful in the treatment of metastasis or rheumatoid arthritis....

20050272792 - Benzimidazoles, process for their preparation and use thereof as medicament: e

20050272795 - Prevention and treatment of benign prostatic hyperplasia: A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidamine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis....

20050272796 - Prevention and treatment of benign prostatic hyperplasia using lonidamine and lonidamine analogs: A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidamine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis....

20050272793 - Pyrazole compounds and uses related thereto: Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome....

20050272794 - Pyrazole derivatives, compositions containing such compounds and methods of use: Pyrazoles having a naphthyl group attached are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included....

20050272797 - Processes for preparation of bicyclic compounds and intermediates therefor: A process for preparing intermediate compound (VII), compound (VIII) and compound (XIV) which will be raw materials for the synthesis of a synthetic antibactrial compound, via compound (I) or compound (X) and then, compound (II), the compounds each being shown below; and novel compounds useful for the preparation....

20050272798 - Disulfide prodrugs and linkers and stabilizers useful therefor: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides...

20050272799 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds....

20050272800 - Nk1 antagonists: The invention is to compounds exhibiting neurokinin inhibitory properties, pharmaceutical compositions comprising same and methods of treatment for neurokinin-mediated conditions....

20050272801 - Isoprenoid pathway inhibitors for stimulating cartilage growth: R5 is H or linear, branched or cyclic alkyl, and R′ represents a cation, H or a substituted or unsubstituted alkyl group of 1-6C, promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic...

20050272802 - Process for preparing form i of tegaserod maleate: A process for preparing Form I of tegaserod maleate comprises the steps of: (i) dissolving tegaserod in a solvent; (ii) optionally, subjecting the solution to activated carbon treatment; (iii) adding maleic acid solution to the tegaserod solution; and (iv) isolating crystalline Form I of tegaserod maleate....

20050272803 - Phosphodiesterase 4 inhibitors: p

20050272804 - Methods of delaying alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor: The present invention relates to compositions and methods of treating a cognitive disorder in a subject by administering an effective amount of a phenserine compound or a pharmaceutically acceptable salt or ester thereof and an effective amount of a HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof to...

20050272805 - Treatment of gastrointestinal disorders with duloxetine: The present invention belongs to the fields of medicinal and pharmaceutical chemistry, and provides a new method of treating gastrointestinal disorders by the administration of duloxetine....

20050272806 - Injectable formulations of taxanes for cad treatment: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed...

20050272807 - Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel: A process is provided for the semi-synthesis of taxane intermediates useful in the preparation of paclitaxel and docetaxel, in particular, the semi-synthesis of protected taxane intermediates....

20050272808 - Compositions and methods for the treatment of hypertension: The present invention relates to use of 1,7-dioxaspiro[5.5]undecane and derivatives thereof for the preparation of a medicament for the treatment or prevention of hypertension. The invention also provides a method for treatment or prevention of hypertension using a medicament comprising 1,7-dioxaspiro[5.5]undecane or a derivative thereof as an active ingredient, such...

20050272810 - Compositions comprising nebivolol: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular...

20050272809 - Remedies: wherein R1 and R2 are taken together with the carbon atom to which they are bound, respectively, to form a hydroxydimethyl hexane ring, or where R1 is a hydroxyl group, R2 is an isohexenyl group, a derivative thereof, or a salt thereof. Also, the present invention relates to a therapeutic...

20050272811 - Difluorobenzo-1,3-dioxoles: The invention relates to difluorobenzo-1,3-dioxoles, to a process for their preparation, and to their use for preparing medicaments and crop protection agents....

20050272812 - Methor for use of acetyl-l-carnitine (alcar) for treatment of depressive disorders in humans: Depression and bi-polar depression are treated with an acetyl-L-carnitine (ALCAR), thereby avoiding unwanted side-effects exhibited by conventional antidepressant agents. ALCAR also helps prevents recurrent episodes of depression and bi-polar depression and both provides beneficial membrane phospholipid and high-energy phosphate changes in a brain of human subjects with major depressive disorders...

20050272813 - Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis: Novel synthetic forms of etherified oxidized phospholipids and methods of utilizing same for preventing and treating atherosclerosis and other related disorders, as well as inflammatory disorders, immune mediated diseases, autoimmune diseases and proliferative disorders, are provided. In addition, methods of synthesizing etherified and esterified oxidized phospholipids and of using same...

20050272814 - Medicine for prevention or treatment of diabetes: The present invention provides a medicine for preventing or treating a diabetes, which includes 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof, and metformin as active ingredients. The present invention provides a method for preventing or treating a diabetes, which includes administering 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid or a pharmacologically acceptable salt thereof,...

20050272815 - Compounds and compositions for delivering active agents: Modified amino acid compounds useful in the delivery of active agents are provided. The active agents can be peptides. Methods of administration, such as oral, subcutaneous, sublingual, and intranasal administration and methods of preparation of the modified amino acid compounds are also provided....

20050272816 - 3,5,3' -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof: The invention regards the use of triiodothyronine sulfate, commonly named T3S, as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine (T3), as such or in association with thyroxine (T4), and pharmaceutical formulations thereof....

20050272817 - Dermatological use and a dermatological preparation: The present invention concerns a dermatological use, a dermatological preparation and a method of treatment to inhibit or reduce the thyroid hormone activity of L-thyroxine and its metabolite L-triiodothyronine, which accelerate cellular metabolism and proliferation. A topical pharmaceutical preparation containing a thyronine derivative inhibiting the thyroid hormone activity of L-thyroxine...

20050272818 - Novel process for producing ibuprofen sodium dihydrate: Disclosed herein is a novel process for producing Sodium dihydrate salt of Ibuprofen of Formula (Structure I) by treating a salt of long chain carboxylic acid of Formula (Structure III) with Ibuprofen of Formula (Structure II) in the presence of an aqueous organic solvent....

20050272819 - Use of alkylureas for treating acne: Methods of treating acne are provided. The methods involve applying to the acne an alkyl urea in a pharmaceutically acceptable carrier. The use of an alkyl urea in the manufacture of a medicament for the treatment of acne is also provided. Compositions of alkyl ureas in a pharmaceutically acceptable carrier...

20050272820 - Nontoxic killer of e. coli and other problem microorganisms: The present invention provide a composition of non-toxic low-cost ingredients that effectively kill pathologic bacteria and methods for use of the composition. The present invention comprises novel compositions and methods for controlling enteric pathogens and spoilage organisms such as Salmonella, Escherichia, Campylobacter, Listeria, Pseudomonas and Enterobacteracae on the surface of...

20050272821 - Levalbuterol hydrochloride polymorph a: The invention is directed to processes for making levalbuterol HCl Polymorph A from by suspending or forming a first slurry of (R)-SLB(D)-DBTA in at least a first organic solvent, adding HCl to the suspension or slurry of the solid (R)-SLB.D-DBTA until the (R)-SLB.D-DBTA forms levalbuterol HCl Polymorph A, and isolating...

20050272822 - Venlafaxine hydrochloride monohydrate and methods for the preparation thereof: This invention relates to novel crystalline polymorphic form of venlafaxine hydrochloride which exists in hydrated form (e.g., as a monohydrate), methods for the preparation thereof, and its use....

20050272823 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents: i

20050272824 - Methods for monitoring combretastatin resistance: Methods and diagnostic kits for monitoring combretastatin resistance are provided....

20050272825 - Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women: t

20050267010 - Bi-lateral local renal delivery for treating congestive heart failure and for bnp therapy: The invention relates to systems and methods for local renal delivery of agents to subjects that are at risk for congestive heart failure and other conditions. The invention encompasses devices for renal drug delivery and methods of use....

20050267011 - Coupling of excitation and neurogenesis in neural stem/progenitor cells: Coupling of excitation to neurogenesis in proliferating post-natal NPCs is demonstrated in vitro and in vivo. Neurogenesis is potently enhanced by excitatory stimuli, and involves Cav1.2/1.3 channels and NMDA receptors. These Ca2+ influx pathways are located on the proliferating NPCs, allowing them to directly sense and process excitatory stimuli. Excitation...

20050267012 - Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma: Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities....

20050267009 - Method of treatment of acute and persistent pain: Biochemical mediators of inflammation facilitate persistent pain disorder. Treatment follows a multilevel pain gate model to enable site-specific application of appropriate inhibitors that block receptor sites. The result often is the effective treatment of the pain disorder by the administration of lower dosages of the inhibitors than used according to...

20050267013 - Methods for affecting various diseases utilizing lxr compounds: The present invention relates to methods for elevating high density lipoprotein (HDL) plasma levels, decreasing the absorption of dietary cholesterol in the intestine, decreasing the plasma level of low density lipoprotein (LDL), and increasing the conversion of cholesterol to bile acids, utilizing LXRβ selective agonists, usually without elevating the plasma...

20050267014 - Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid: The present invention relates to compositions comprising factor VII or a factor VII-related polypeptide and tranexamic acid, and the use thereof for treating bleeding episodes....

20050267015 - Method of treatment and composition for inhibiting the production of toxic free radical and reactive oxygen species using metalloproteins found in bacteria: Compositions and methods for treating, reducing the risk of, or slowing the onset of a neurological disorder or pathological condition in a subject are provided. An inhibitor of the formation of free radical or reactive oxygen species is administered in an effective amount to the subject and the inhibitor prevents...

20050267016 - Cd-10 activated prodrug compounds: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing...

20050267017 - Conformationally constrained c-backbone cyclic peptides: Backbone cyclized peptide analogs that include at least one building unit of a Cα(ω-functionalized) amino acid that is constructed to include a spacer and a terminal functional group. The bridging groups are attached via alpha carbons of amino acid derivatives to provide novel non-peptide linkages. Also disclosed are novel Cα(ω-functionalized)...

20050267019 - Echinocandin derivatives, their method of preparation and their application as anti-fungal agents: c

20050267018 - Macrocyclic compounds as inhibitors of viral replication: The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an...

20050267026 - Combination dosing regimen for erythropoietin: The present invention provides a combination dosing regimen for erythropoietin (EPO). More particularly, the present dosing regimen includes administration of at least a first dosing segment comprising a first exposure to EPO capable of stimulating the production of reticulocytes followed by a second exposure to EPO capable of sustaining the...

20050267025 - Compositions and methods for treatment of infectious and inflammatory diseases: The present invention relates to a vaccine for preventing Mycobacterium tuberculosis infection that contains a polypeptide isolated from Mycobacterium tuberculosis that suppresses the immune response and induces IL-10 in a subject infected with Mycobacterium tuberculosis, and to methods of treating an inflammatory condition in a mammal, vaccinating a mammal against...

20050267029 - Compounds which modulate amyloidogenesis and methods for their identification and use: A cell culture system for amyloidogenesis and methods for use of this cell culture system in identifying amyloid modulating compounds are provided. Also provided are compounds and methods for modulating the interaction of an amyloid polypeptide and heparan sulfate and for treating amyloid-associated diseases....

20050267021 - Cystatin c as an antagonist of tgf-beta and methods related thereto: Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of...

20050267022 - Identification of novel factors that block programmed cell death or apoptosis by targeting jnk: Methods and compositions for modulating apoptosis by acting on the c-Jun-N-terminal kinase (JNK) pathway and assays for the isolation of agents capable of modulating apoptosis, including modulators of the JNK pathway are disclosed. A method of modulating JNK pathway independent of Gadd46β is disclosed. Methods and compositions are presented for...

20050267024 - Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth...

20050267023 - Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms: The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more...

20050267034 - Modified exendins and exendin agonists: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions...

20050267033 - Multi-dose erythropoietin formulations: The present invention is directed to multi-dose erythropoietin formulations for parenteral administrations. The formulations contain one or more of the following preservatives benzethonium chloride, phenoxyethanol and phenylethyl alcohol....

20050267020 - Polypeptides derived from inducible hsp70 and pharmaceutical compositions containing the same: A peptide comprising an amino acid sequence of at least 8 contiguous amino acids, the amino acid sequence being at least 65% identical to a portion of the same length within the amino acid sequence of inducible Hsp70, characterized in that the peptide amino acid sequence differs from any amino...

20050267032 - Sulfone-containing prodrugs: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfone-containing prodrugs, and compositions and methods utilizing sulfone-containing prodrugs that are useful in the treatment of diseases by blocking potassium...

20050267028 - Therapeutic peptides: The present invention provides a ligand isolated from Moraxella catarrhalis outer membrane protein which binds to CEACAM receptors, said ligand comprising a receptor binding domain comprising an amino acid sequence selected from the group disclosed, or a fragment, homologue, functional equivalent, derivative, degenerate or hydroxylation, sulphonation or glycosylation product or...

20050267031 - Therapeutic pore-forming peptides: A class of procytotoxic agents is characterized by a capability to kill with target cell-specificity. Such an aspect can be a pore-forming protein which has at least one lysine residue, modified by a peptide linkage to an amino acid residue, via the epsilon amino group. These agents are useful in...

20050267030 - Use of deltapkc peptides for modulation of reactive oxygen species: Methods for modulating the level of reactive oxygen species (ROS) in a cell or tissue by administering compounds that modulate the activity of δPKC are described. In one embodiment, the level of ROS is decreased by administering a peptide effective to inhibit the activity of δPKC. In another embodiment, the...

20050267027 - Use of erythropoietin for treatment of cancer: A method for treating cancer is provided. The method involves administering to subjects in need of such treatment an effective amount of erythropoietin of an analog thereof effective to inhibit angiogenesis in a tumor. Also provided are methods to reduce HIF-1α protein levels and/or VEGF expression, particularly in tumors....

20050267035 - Peptide and polypeptide inhibitors of complement c1s: The complement system plays an important role in providing resistance to infections and in the pathogenesis of tissue injury. Yet an inappropriate activation of complement can result in a variety of disorders. The present invention provides C1s catalytic site-directed moieties, C1s exosite binding moieties, and bivalent polypeptide inhibitors comprising such...

20050267037 - Methods and compositions for treating cancer using proteasome inhibitors: The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a...

20050267038 - Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use: e

20050267036 - Peptides of cav2.2 that inhibit pain: The present invention relates to peptides of CaV2.2 and their use in the treatment of pain. The sequence of the peptides is derived from the C-terminus of CaV2.2. and is believed to inhibit the interaction of CaV2.2 with Mint1-PDZ1. The invention is related to use of this peptide to treat...

20050267039 - Il-16 antagonists: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and...

20050267040 - Hepatitis c virus inhibitors:

20050267041 - Tetrapeptide derivative crystals: The invention provides crystals of N2-(N,N-dimethyl-L-valyl)-N-[(1S, 2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide or salts thereof which possess potent antitumor activity and methods for their preparation....

20050267042 - Method and preparation for binding acetaldehyde in saliva, stomach and large intestine: The object if the invention is the use of compounds comprising one or more free sulphlydryl or amino groups for preparing a pharmaceutical composition for locally binding acetaldehyde in saliva, the stomach or the large intestine, and pharmaceutical compositions comprising the said compounds....

20050267044 - Novel compounds and compositions as cathepsin s inhibitors: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making....

20050267043 - Novel inhibitors of hepatitis c virus ns3 protease: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease....

20050267047 - Diarylalkanes as potent inhibitors of binuclear enzymes: The present invention implements a strategy that combines an enzyme inhibition assay with a chemical dereplication process to identify active plant extracts and the particular compounds—diarylalkanes and/or diarylalkanols within those extracts that specifically inhibit binuclear enzyme function. Included in the present invention are compositions of matter comprised of one or...

20050267046 - Geldanamycin compounds and method of use: e

20050267045 - Method for preparing peritoneal dialysate: Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds...

20050267049 - Anti-hypercholesterolemic compounds: r

20050267048 - Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae:

20050267051 - Antineoplastic and anti-hiv conjugates of steroid acid and nucleosides: A conjugate comprising a nucleoside ester of a steroid acid, said steroid acid having a cyclopentanophenanthrene carbon-carbon skeleton or a homolog thereof and containing up to a maximum of 40 carbon atoms and having at least one carboxylic group covalently bonded thereto, said ester exhibiting at least one activity selected...

20050267050 - Compositions and methods for treating mdma-induced toxicity: This invention relates to methods and compositions for treating or preventing the symptoms associated with toxicity induced by ingestion of MDMA. In one aspect, the present invention is related to methods for treating or preventing the symptoms associated with MDMA, or MDMA-related psychoactive drugs by administering to a subject in...

20050267052 - Epicatechin for hypertension treatment: Disclosed and claimed are flavanols, e.g. epicatechin, compositions such as pharmaceutical compositions containing an effective amount of flavanols, e.g. epicatechin, and methods of treatment or prevention of hypertension using the same....

20050267053 - Use of macrolides in pest control: There is now described a method of controlling pests with macrolide compounds; more specifically A) a method of controlling pests in and on transgenic crops of useful plants, such as, for example, in crops of maize, cereals, soya beans, tomatoes, cotton, potatoes, rice and mustard, with a macrolide compound, characterized...

20050267054 - Antibacterial compounds with improved pharmacokinetic profiles: e

20050267055 - Agent for improvement of glucose tolerance: The present invention provides a glucose tolerance improving agent containing as an active ingredient at least one triterpene selected from the group consisting of corosolic acid, an analogous compound of corosolic acid, and a pharmaceutically acceptable salt thereof....

20050267056 - Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives: Methods and compositions are provided for efficiently preparing and manufacturing pentostatin. Also provided are novel precursors of pentostatin, pentostatin analogs and derivatives. In one aspect of the invention, a method is provided for total chemical synthesis of pentostatin via a route of heterocyclic ring expansion. For example, a heterocyclic pharmaceutical...

20050267063 - Antisense modulation of p70 s6 kinase expression: Antisense compounds, compositions and methods are provided for modulating the expression of p70 S6 kinase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding p70 S6 kinase. Methods of using these compounds for modulation of p70 S6 kinase expression and for treatment of diseases associated with...

20050267060 - Combinatorial methods and compositions for treatment of melanoma: The present invention provides a rational basis for combining targeted therapies together with selected chemotherapeutics, which does not currently exist for the treatment of melanoma. The present invention is based on the present inventors' discovery that Akt3 regulates apoptosis and V599E B-Raf regulates growth and vascular development in melanoma. Inventors...

20050267057 - Immunostimulatory nucleic acid molecules: Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity, and B cell proliferation are disclosed. The sequences are also useful a synthetic adjuvant....

20050267064 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed....

20050267061 - Methods and compositions for treating neuropathic and neurodegenerative conditions: Disclosed herein are engineered zinc finger proteins which modulate transcription of the gene encoding vascular endothelial growth factor-A (VEGF-A) and other genes encoding products with neurotrophic activities. Also disclosed are methods for the use of these engineered zinc finger proteins in the treatment of neuropathy (including diabetic neuropathy), and other...

20050267065 - Modulation of aurora b expression: Compounds, compositions and methods are provided for modulating the expression of Aurora B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding Aurora B. Methods of using these compounds for modulation of Aurora B expression and for diagnosis and treatment of diseases and conditions associated with expression of Aurora B...

20050267062 - Regulation of angiogenesis with zinc finger proteins: Provided herein are a variety of methods and compositions for regulating angiogenesis, such methods and compositions being useful in a variety of applications where modulation of vascular formation is useful, including, but not limited to, treatments for ischemia and wound healing. Certain of the methods and compositions accomplish this by...

20050267058 - Rna interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating placental growth factor (e.g., PGF-1 or PlGF-1, PGF-2 or PlGF-2, and/or PGF-3 or PlGF-3) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity...

20050267059 - Syk-targeted nucleic acid interference: The present invention provides methods and compositions for attenuating expression of Spleen Tyrosine Kinase, Syk. In general, the described methodology involves the use of RNAi constructs that are targeted to a Syk mRNA sequence....

20050267066 - Pharmaceutical composition comprising a cdk inhibitor and gemcitabine: A first aspect of the invention relates to a combination comprising a CDK inhibitor and gemcitabine. A second aspect of the invention relates to a pharmaceutical product comprising a CDK inhibitor and gemcitabine as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the...

20050267067 - Radical reaction inhibitors, method for inhibition of radical reactions, and use thereof: The present invention has an object to provide a radical reaction inhibitory agent for inhibiting unsaturated compounds from decomposing through radical reactions, a method for inhibiting the formation of free radicals from unsaturated compounds and radical reactions thereof, and a composition which is suppressed in radical formation, radical reaction, or...

20050267068 - Dried and agglomerated hyaluronic acid product: The present invention relates to products comprising hyaluronic acid or a salt thereof, which product is dried and agglomerated as defined herein, various compositions and articles comprising the product or compositions of the invention, methods of producing the product of the invention, and uses thereof....

20050267069 - Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease: This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer....

20050267070 - Process for the preparation of esters of heparin: The description relates to a process for the production of esters of heparin, wherein from 0.1 to 2 g of a halogenated reagent having the formula R—CH2—X, where R is a phenyl group which is non-substituted or substituted by a halogen atom or by a nitro group, and X is...

20050267071 - Inhibitors of coronavirus protease and methods of use thereof: This invention provides organic boron-containing compounds, compositions thereof, and methods of using such compounds and compositions for inhibiting coronavirus protease(s) and for treating infections....

20050267072 - Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction: The present invention relates to the novel medicinal use of dually acting compounds capable of inhibiting neutral endopeptidase (=NEP) and human soluble endopeptidase (=hSEP) in the prophylaxis and/or treatment of sexual dysfunction in mammals and humans....

20050267073 - Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or...

20050267074 - Resistance-repellent retroviral protease inhibitors: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided....

20050267075 - Sulfonylethyl phosphorodiamidates: Sulfonylethyl and thioethyl phosphorodiamidates, their preparation and intermediates in their preparation, formulations containing them, and their pharmaceutical use. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies....

20050267076 - Method for improving cognitive function: Methods and compositions for improving cognitive function by co-administration of donepezil and a GABAB receptor antagonist are provided....

20050267077 - Method for improving cognitive function by co-administration of a gabab receptor antagonist and an acetylcholinesterase inhibitor: The present invention provides methods and compositions for improving cognitive function by administering a GABAB receptor antagonist and an acetylcholinesterase inhibitor....

20050267078 - Combinations comprising antimuscarinic agents and beta-adrenergic agonists: Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma...

20050267079 - Tetracycline derivatives and methods of use thereof: A treatment for inhibiting microbial or tumor growth is disclosed, which comprises adding to a subject in need of treatment an effective amount of one or more tetracycline derivatives....

20050267080 - Methods and related compositions for reduction of fat: Compositions and methods useful in the reduction of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion or anti-dispersion agents and pharmaceutically acceptable excipients. The pharmacologically active detergent compositions are useful for treating...

20050267083 - Dosage form for hormonal contraception: The present invention relates to a dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, characterised in that the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid...

20050267082 - Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate: The present invention relates to a hormonal contraceptive including at least 120 hormone-containing daily units, which contain 5 to 50 μg of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate, and optionally 7 to 3 hormone-free daily units for uninterrupted oral administration to women....

20050267084 - Hormonal contraceptive containing a combination of ethinyloestradiol and chlormadinone acetate: The present invention relates to a hormonal contraceptive including 21 to 25 hormone-containing daily units, which contain a combination of ethinyloestradiol in an amount of ≧25 μg and chlormadinone acetate in an amount of ≧5 mg, and optionally 7 to 3 hormone-free daily units for oral administration to women....

20050267081 - Use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation: The invention relates to the use of a combination of ethinyloestradiol and chlormadinone acetate to produce a pharmaceutical preparation for the treatment of androgen-induced disorders and for hormone replacement therapy and for the treatment of dysmenorrhoea and for stabilising the menstrual cycle and for the treatment of menstrual cycle-dependent complaints...

20050267085 - Combined therapy for the treatment of parkinson's disease: The present invention concerns a method and a pharmaceutical composition for treating the symptoms associated to Parkinson's disease. The method and the pharmaceutical composition use a combination of a therapeutically effective amount of at least one of DHEA or DHEA-S in combination with a therapeutically effective amount of a dopamine...

20050267086 - Compounds and methods for cytoprotection: e

20050267088 - Compositions for treating hyperemia: The present compositions advantageously treat hyperemia with substantially no added irritation to the eye. In one embodiment, the compositions include an ophthalmically acceptable carrier component, a vasoconstrictor component in an amount effective to treat hyperemia when the composition is administered to an eye, and a polyanionic component in an amount...

20050267087 - Inflammatory eye disease: The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors....

20050267089 - Polycyclic pyrimidines as potassium ion channel modulators: The present invention provides a genus of polycyclic pyrimidines that are useful as modulators of potassium ion channels. The modulators of the invention are of use in both therapeutic and diagnostic methods....

20050267090 - Photoactive metal nitrosyls for blood pressure regulation and cancer therapy: Disclosed are nitric oxide delivery agents and methods of their use, more specifically to photoactive compounds, which are able to perform targeted delivery of nitric oxide in vitro and in vivo and are useful for medicinal applications including, but not limited, to blood pressure regulation and cancer treatment....

20050267091 - Compositions containing policosanol and niacin and/or niacin derivatives and their pharmaceutical uses: A composition is provided which contains policosanol and niacin and/or niacin derivatives and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, coronary heart disease (heart attacks and strokes), inflammation, immunoregulatory diseases, cardiovascular diseases, deep vein thrombosis, anxiety, depression and/or neurodegenerative...

20050267092 - Novel cephalosporin compounds and process for preparing the same: The present invention relates to a novel cephalosporin compound, and pharmaceutically acceptable non-toxic salt, physiologically hydrolysable ester, hydrate, solvate or isomer thereof, to a pharmaceutical composition comprising the compound, and to a process for preparing the compound....

20050267095 - 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands: The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H3 ligands and are useful in...

20050267093 - Amide compounds with mch antagonistic activity and medicaments comprising these compounds: e

20050267094 - Amino ceramide-like compounds and therapeutic methods of use: The present invention provides amino ceramide-like compounds which inhibit glucosyl ceramide (GlyCer) formation by inhibiting the enzyme GlyCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore useful in therapeutic methods for treating various conditions and diseases...

20050267096 - New indazole and indolone derivatives and their use pharmaceuticals: which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 over D2. These compounds are useful for the treatment and/or prevention of sexual dysfunction, for example female sexual dysfunction (FSD), in particular female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD;...

20050267097 - Lactam-containing compounds and derivatives thereof as factor xa inhibitors: i

20050267098 - Modulators of cellular adhesion: and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular...

20050267099 - Synthesis of olanzapine and intermediates thereof: Olanzapine and salts thereof are made by a process that utilizes an N-formyl olanzapine intermediate of formula (4) or a salt thereof....

20050267100 - Tetraazabenzo[e]azulene derivatives and analogs thereof: a

20050267102 - Inhibition of matrix metalloproteases by substituted biaryl oxobutyric acids: These compounds are useful for inhibiting matrix metalloproteases and, therefore, combating conditions to which MMP's contribute, such as osteoarthritis, rheumatoid arthritis, septic arthritis, periodontal disease, comeal ulceration, proteinuria, aneurysmal aortic disease, dystrophobic epidermolysis, bullosa, conditions leading to inflammatory responses, osteopenias mediated by MMP activity, tempero mandibularjoint disease, demyelating diseases of...

20050267101 - Treatment of diseases using ice inhibitors: This invention relates to methods and compositions for treating autoinflammatory diseases. The invention also assays for evaluating the ability of an ICE inhibitor to treat autoinflammatory diseases....

20050267103 - Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders: The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1....

20050267104 - Acyloxymethylcarbamate prodrugs of oxazolidinones: The present invention relates to acyloxymethylcarbamate oxazolidinones. The compounds of the present invention have potent activity with excellent oral bioavailability against Gram-positive and Gram-negative bacteria....

20050267105 - Bicyclic heterocycles as hiv integrase inhibitors: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV....

20050267106 - New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments: e

20050267107 - 4-alkyl-/4-alkenyl-/4-alkynyl methyl/-1-aryl-cyclohexylamine compounds:

20050267108 - Indole compounds:

20050267110 - Propane-1, 3-dione derivative: Provided is a pharmaceutical composition containing a propane-1,3-dione derivative as the active ingredient, particularly a GnRH receptor antagonist. Also, provided is a propane-1,3-dione derivative having a GnRH antagonistic effect....

20050267109 - Pyridyl-triazine derivatives as microbiocidal active substances: Triazine derivatives of formula (1) wherein R1 is C1-C20alkyl; C3-C7cycloalkyl; or C1-C20perfl C1-C20alkyl; or C3-C7cycloalkyl; and R3 is hydrogen; C1-C20alkyl; C3-C7cycloalkyl; C1-C20perfluoroalky; C1-C20alkyl-carbonyl; C3-C7cycloalkyl-carbonyl; C1-C20perfluoroalkyl-carbonyl; or phenylcarbonyl; are described. The compounds exhibit pronounced action against gram-positive and gram-negative bacteria and also against yeasts and moulds. They are also suitable for...

20050267111 - Pharmaceutical compositions and methods for use: The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention....

20050267112 - Novel imidazotriazinones and the use thereof: e

20050267113 - Novel pyridazine derivatives and medicines containing the same as effective ingredients: wherein R1 represents a (substituted) aryl group, R2 represents a phenyl group substituted at 4-position by a lower alkoxyl group or a lower alkylthio group, R3 represents a lower alkoxyl group, a halogenated lower alkyl group, a lower cycloalkyl group, a (subsituted) aryl group, a (substituted) aryloxy group, a (substituted)...

20050267115 - Alkyne compounds with mch antagonistic activity and medicaments comprising these compounds: e

20050267116 - Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines: Novel substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or...

20050267114 - Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient: (wherein all of the symbols have the same meanings as defined in specification.), quaternary ammonium salts thereof, N-oxides thereof or salts thereof. The compounds represented by formula (I) are used for prevention and/or treatment of various inflammatory diseases (asthma, nephritis, nephropathy, hepatitis, arthritis, chronic rheumatoid arthritis, rhinitis, conjunctivitis, ulcerative colitis...

20050267117 - Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin: T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in...

20050267118 - Inhibitors of factor xa and other serine proteases involved in the coagulation cascade: wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula I, processes for preparing compounds of Formula I, and intermediates...

20050267119 - Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity....

20050267120 - Alkyne compounds with mch antagonistic activity and medicaments comprising these compounds: e

20050267121 - Aralkyl-alcohol peiperazine derivatives adn their uses as antidepressant:

20050267122 - Ansamycins having improved pharmacological and biological properties: Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives described are dimers. These and others described can include one or more solubilizing groups that have...

20050267123 - 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade: The present invention relates to compounds, and prodrugs thereof, compositions and methods useful for preventing and treating thrombotic conditions in mammals. The compounds of the present invention, and prodrugs thereof, selectively inhibit certain proteases of the coagulation cascade....

20050267124 - Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous producing system and pdev inhibiitors: A combination therapy for the inhibition and/or treatment of sexual dysfunction and/or cardiovascular diseases in humans and other mammals, by administering a synergistic combination of at least one inhibitor of neutral endopeptidase, at least one inhibitor of the endogenous endothelin producing system, and at least one inhibitor of phosphodiesterase 5....

20050267125 - High drug load tablet: c

20050267126 - Compounds derived from aryl carbamates, preparation thereof and uses of same: The invention concerns novel compounds, preparation and uses of same, particularly therapeutic. More particularly, the invention concerns compounds derived from arylcarbamates, preparation and uses of same, particularly in the field of human or animal health. The inventive compounds are preferably ligands of serotoninergic 5-HT4 receptors, and can therefore be used...

20050267127 - Guanidino phenylalanin compounds used as urokinase inhibitors: The invention relates to the use of derivatives of 3-guanidinophenylalanine as urokinase inhibitors for treating malignant tumors and metastasis....

20050267128 - Compounds, compositions and methods of modulating the mitochondrial apoptosis-induced channel (mac): The present invention relates to methods of treating conditions or diseases in which apoptosis is either desirable or undesirable. In particular, in conditions whereby it is desirable to inhibit unwanted cellular proliferation such as in cancers or in hyperproliferative disorders, treatment with an agent that promotes opening of the mitochondrial...

20050267129 - Dipeptide nitrile cathepsin k inhibitors: In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring, and Het is an optionally substituted nitrogen-containing heterocyclic substituent, are provided, useful e.g. for therapeutic or prophylactic treatment of a disease...

20050267130 - Tetrahydrocarboline antiviral agents: The invention encompasses a series of tetrahydrocarboline compounds of Formula I which inhibit HIV entry by attaching to the exterior viral envelop protein gp120 and interrupting the viral entry process, possibly by interfering with the cellular receptor CD4. This action makes the compounds useful for treating HIV infection and AIDS....

20050267131 - Bicyclic heterocycles as hiv integrase inhibitors: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with...

20050267132 - Bicyclic heterocycles as hiv integrase inhibitors: The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with...

20050267133 - Pyrazolopyrimidines as kinase inhibitors: The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds...

20050267134 - Non-nucleotide composition and method for inhibiting platelet aggregation: This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis or related disorders. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a non-nucleotide compound,...

20050267135 - Combinations comprising antimuscarinic agents and pde4 inhibitors: Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma...

20050267137 - Cyclopropane cgrp antagonists, medicaments containing these compounds, and method for the production thereof: m

20050267136 - Method of inhibiting dihydrofolate reductase; screening assay for the identification of novel therapeutics and their cellular targets: A novel screening assay for identifying therapeutic agents and their cellular targets is described. The assay is useful in developing new antibacterial, antifungal, antiparasitic and anti cancer therapeutics. New inhibitors of dihydrofolate reductase (DHFR) have been identified and their cellular target confirmed using the assay of the present invention. Methods...

20050267138 - Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods: n

20050267139 - Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods:

20050267140 - Method for treating abnormal cell growth: Therapeutic pharmaceutical compositions and methods of treatment of abnormal cell growth comprising a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof in combination with an oral camptothecin, an oral camptothecin derivative, an indolopyrrocarbazole derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment of...

20050267141 - Process to prepare camptothecin derivatives: A process is provided for the preparation of camptothecin derivatives, such as irinotecan, in a one-pot operation....

20050267142 - Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods: p

20050267143 - Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof: The invention includes compositions comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human...

20050267144 - Methods of stimulating immune response in virally infected individuals: Methods to stimulate host immune system against viral infections associated with common colds are disclosed. Methods to stimulate immune response of a virally infected individual through an immuno modifier such as a non-nucleoside imidazoquinolinamine (heterocyclic amine) are disclosed....

20050267145 - Treatment for lung cancer: The present invention provides methods, pharmaceutical compositions, and pharmaceutical combinations useful for treating lung cancer. Generally, the compositions include a 5-LO inhibitor in an amount effective to inhibit 5-lipoxygenase in an inhalable formulation. In some cases, the formulation may further include an IRM compound. Generally, the pharmaceutical combinations include a...

20050267146 - 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors: e

20050267148 - Benzimidazole derivative:

20050267147 - Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament:

20050267149 - Benzoic acid derivatives as modulators of ppar alpha and gamma: A compound of formula (I) wherein R1 represents aryl optionally substituted by a heterocyclic group or a heterocyclic group optionally substituted by aryl wherein each aryl or heterocyclic group is optionally substituted; the group —CH2)m-T-(CH2)n—U—(CH2)p— is attached at either the 3 or 4 position in the phenyl ring as indicated...

20050267150 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds: Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions that include a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such...

20050267151 - Process for preparing acyclic hcv protease inhibitors: s

20050267152 - Gly1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders:

20050267154 - Novel glucose sensor: Methods are provided for the modulation of hSGLT3 protein glucosensor activity. The sensor is expressed in cholinergic neurons that regulate muscle activity, and in tissues including the brain and pacreas. The present invention also provides methods of identifying therapeutic compounds that modify the function of these sensors. Such therapeutic compounds...

20050267153 - Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections: Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents,...

20050267155 - Constrained himbacine analogs as thrombin receptor antagonists: X is —O— or —NR6— when the double-dashed line represents a single bond; X is H, —OH or —NHR20 when the double-dashed line represents an absent bond; and other parameters are as defined herein. Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor...

20050267160 - 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives: New benzimidazole derivatives are described, their production and their use for the production of pharmaceutical agents for treatment and prevention of diseases that are associated with a microglia activation and T-cell-mediated immunological diseases, as well as pharmaceutical preparations that contain the new benzimidazole derivatives....

20050267156 - Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors: wherein R1 is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C1-6alkyl, hydroxy, amino, halogen, aminoC1-4alkyl and mono- or di(C1-4alkyl)amino; R2 is hydrogen or C1-6alkyl; L is a direct bond, —O—, C1-6alkanediyl-O— or —O—C1-6alkanediyl; R3 is phenylC1-4alkyl; R4 is C1-6alkyl; R5...

20050267159 - Magnesium complexes of s-omeprazole: pharmaceutical compositions and processes of making the same. In formula (I), solva, solvb, and solvc represent solvent molecules where x and y are independently selected from integers 0 to 6, the sum of which is 4 or 6, while z is a positive rational number from 0 to 6. The...

20050267157 - Magnesium-s-omeprazole: pharmaceutical compositions and processes of making the same. In formula (I), solva, solvb, and solvc represent solvent molecules where x and y are independently selected from integers 0 to 6, the sum of which is 4 or 6, while z is a positive rational number from 0 to 6. The...

20050267158 - Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2 pyridin-2-yl-vinyl)-1h-indazol-6-ylamino]-phenyl}-amide: The invention provides several polymorphic forms and an amorphous form of 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide, pharmaceutical compositions containing such polymorphic or amorphous forms, and methods of using such pharmaceutical compositions to treat disease states mediated by protein kinases, such as cancer and other disease states associated with unwanted angiogenesis and/or cellular...

20050267162 - Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione: A substantially non-hydrated and non-hygroscopic or slightly hygroscopic hydrochloride salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione; a pharmaceutical composition containing such a compound, a process of preparing such a compound and the use of such a compound in medicine....

20050267161 - Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity: s

20050267163 - Vanilloid receptor ligands and their use in treatments: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic...

20050267164 - Imidazolidinone compounds: d

20050267165 - Il-8 receptor antagonists: This invention relates to the novel use of dianilino squarates in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8)....

20050267166 - Continuous dosing regimen: Compositions comprising one or more cancer drugs, continuous oral dosing schedule with drugs which bind to the colchicine site of tubulin β-subunits, and methods of treating diseases using continuous dosing schedules are disclosed....

20050267167 - Pentanoic acid derivatives: wherein n is 0 or 1, R11 is hydrogen and chlorine, R5 is R7—CH2— or R8, or R5 and R11, taken together is alkylidene; R6 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR9R10, in which R9, R10 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or...

20050267168 - Pentanoic acid derivatives: wherein n is 0 or 1, R11 is hydrogen and chlorine, R5 is R7—CH2— or R8, or R5 and R11, taken together is alkylidene; R6 is hydroxy, alkoxy, alkoxy substituted by phenyl, NR9R10, in which R9, R10 is (i) hydrogen, (ii) alkyl, (iii) phenyl, (iv) phenyl substituted by alkoxy or...

20050267170 - Substituted methyl aryl or heteroaryl amide compounds: X represents a carbon atom or the like: Y represents imino, or the like: R1 represents an alkyl group having from 1 to 6 carbon atoms or the like: R2 and R3 independently represents a hydrogen atom or the like. These compounds are useful for the treatment of disease conditions...

20050267169 - Watersoluble prodrugs of propofol: The present invention relates to propofol derivatives comprising a cyclic or linear amino acid, or a poly- or (oligo)saccharide moiety, a process for preparing said derivatives, a method for anesthetizing a mammal as well as a method for treating convulsions, migraine or related diseases, or for the inhibition of free...

20050267171 - Alpha-and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors: α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease....

20050267172 - Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof: x

20050267174 - Condensation reagents and a process for their preparation:

20050267173 - Serine protease inhibitors:

20050267175 - Methods, compounds, and diagnostics for cancer treatment: Methods of treating cancer employing isoxazole derivatives are described. Compounds and methods of using these compounds for isolating and/or detecting binding proteins, which may be indicative of a disease, are also described....

20050267176 - Dopamine-agonist combination therapy for improving sleep quality: The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)-N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically...

20050267177 - Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals: e

20050267178 - Novel benzylether derivatives:

20050267180 - Novel oxazole derivatives: wherein wherein R1, R2, R3, R4, R5, R6 and n are as described herein. The compounds of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are modulated by PPARα and/or PPARγ agonists. Examples of such diseases are diabetes, particularly non-insulin dependent diabetes...

20050267179 - Novel thioether derivatives: e

20050267181 - Streptogramin derivatives and compositions thereof: The present invention discloses and claims pharmaceutical compositions comprising Group A streptogramin derivatives of formula (I) and salts thereof in combination with at least one natural group B streptogramin derivative....

20050267182 - Urea derivatives as flt-3 modulators: The invention provides methods and compositions for treating conditions mediated FLT-3. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects....

20050267183 - Selective estrogen receptor modulators: The present invention provides, inter alia, triphenylethylene derivatives, such as, 5-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-1H-tetrazole, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; urinary...

20050267185 - 1,2,4-triazole derivatives, compositions, process of making and methods of use: Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity....

20050267184 - 3-aminocarbonyl substituted benzoylpyrazolones: m

20050267186 - 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds: where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula 1 are useful as...

20050267187 - Process of preparing esters and ethers of probucol and derivatives thereof: e

20050267188 - Benzopyran derivatives substituted with secondary amines including imidazole, their preparation and pharmaceutical compositions containing them: The present invention relates to benzopyran derivatives substituted with secondary amines including imidazole, their preparation, and pharmaceutical compositions containing them. The present invention is pharmacologically useful for the treatment of cancer, rheumatoid arthritis, and diabetic retinopathies through anti-angiogenic properties, and also pharmacologically useful in the protection of heart and neuronal...

20050267189 - Celecoxib compositions: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and...

20050267190 - Solid-state form of celecoxib having enhanced bioavailability: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of...

20050267191 - Process for producing a dipeptidyl peptidase iv inhibitor: e

20050267192 - Bis-indole pyrroles useful as antimicrobials agents: Compounds of Formula I, commonly referred to as bis-indole pyrroles, including isolated naturally-occurring compounds, synthetic and semi-synthetic derivatives thereof having antimicrobial properties and to antimicrobial compositions that include one or more of bis-indole pyrroles and their derivatives or analogs having antimicrobial properties are disclosed. Pharmaceutical compositions comprising such compounds and...

20050267193 - Diindolylmethane formulations for the treatment of leiomyomas: The present invention relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane and diindolylmethane-related indole. The present invention also relates to compositions and methods for treating or preventing leiomyomas by administration of diindolylmethane in combination with an EGFR antagonist. The methods provide non-invasive treatments for...

20050267194 - Indole compounds: e

20050267195 - Drug composition for blood sugar control: The present invention provides pharmaceutical compositions which can achieve good state of glycemic control and correct postprandial hyperglycemia and early morning fasting hyperglycemia. The present pharmaceutical composition is for administration before meal to control blood glucose, which comprises 5 to 45 mg, as a single dose, of mitiglinide or a...

20050267196 - Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the...

20050267197 - Compositions containing policosanol and hmg-co-a reductase inhibitor and their pharmaceutical uses: A composition is provided which contains policosanol and HMG-Co-A reductase inhibitor and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis immunoregulatory diseases, cardiovascular diseases, and/or neurodegenerative disorders in humans and animals. The method comprises...

20050267198 - Novel processes for preparing amorphous atorvastatin hemi-calcium: The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin....

20050267199 - 2-amino- and 2-thio- substituted 1,3-diaminopropanes: e

20050267200 - Heteroaromate osc inhibitors: The present invention relates to heteroaromate OSC inhibitors. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes....

20050267201 - Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same: Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may...

20050267202 - Chromanol derivatives, a process for their production and their use as anti-inflammatory agents: a

20050267203 - Carbamate compounds for use in preventing or treating anxiety disorders: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with...

20050267204 - Synergistic gold-containing compositions: This invention relates to a method of treating an immune-mediated disorder having one or more manifestations. The method comprises administering to a patient requiring such treatment a gold compound and at least one corticosteroid, wherein the at least one corticosteroid is selected to interact synergistically with the gold compound to...

20050267205 - 2,4-dihydroxybenzoic acid derivatives: The present invention relates to novel compounds of formula (I) and to the salts, solvates and prodrugs thereof, wherein the meanings of the various substituents are as disclosed in the description. Said compounds are useful for the treatment or prevention of psoriasis and other immune diseases....

20050267206 - Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders: This invention relates to novel compounds which are thyroid receptor ligands, preferably antagonists, and to methods for using such compounds in the treatment of cardiac arrhythmias, thyrotoxicosis and subclinical hyperthyrodism....

20050267207 - Thyronamine derivatives and analogs and methods of use thereof: Thyronamine derivatives and analogs, methods of using such compounds, and pharmaceutical compositions containing them are disclosed. Methods of preparing such compounds are also disclosed....

20050267208 - Nordihydroguaiartic derivatives for use in treatment of tumors: Nordihydroguaiaretic acid derivatives and methods of use thereof for the treatment of tumors....

20050267209 - Mixed co-crystals and pharmaceutical compositions comprising the same: A mixed co-crystal comprising an API, a first co-crystal former, and a second co-crystal former which is isomorphically substitutable with said first co-crystal former is described. A pharmaceutical composition comprising a mixed co-crystal, methods of making mixed co-crystals, and methods of using mixed co-crystals are also described....

20050267210 - Natural insect repellant: A topical insect repellent with extended duration of protection was obtained from mixtures of molecules based on two or more volatile repellent organic molecular species occurring naturally on the human skin surface. The novel repellent comprises mixtures of lower, intermediate, and higher volatility organic molecules. Active ingredients for formulations are...

20050267211 - Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense: The use of leukotrienes and other products of the 5-lipoxygenase pathway to enhance bacterial defense and treat infections is described. The products are especially useful when administered to the lungs for the treatment of pneumonia and other lower respiratory tract infections. The products may be administered for treatment or prophylactic...

20050267212 - Omega-3 fatty acids in the treatment of depression: The present invention is directed to a method of treating patients with major depression by administering omega-3 fatty acids. These may be administered in a substantially purified form, as part of a pharmaceutical composition, or as part of a larger molecule, e.g., a triacylglycerol, which releases free fatty acid after...

20050267213 - Use of photodynamic therapy to enhance treatment with immuno-modulating agents: Methods of enhancing the efficacy and safety of treatment with immuno-modulating agents are provided. The inventive methods combine treatment with immuno-modulating agents with photodynamic therapy (PDT). PDT can be administered before, during or after administration of the immuno-modulating agent. Combination therapy achieves at least the same efficacy as immuno-modulatory therapy...

20050267214 - Alpha-and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors: Certain Alpha- and Beta-amino acid hydroxyethylamino sulfamic acid derivatives represented by the following formula are useful as retroviral protease inhibitors:...

20050267215 - Abca-1 elevating compounds: The present invention provides compounds that elevate cellular expression of the ABCA-1 gene, promoting cholesterol efflux from cells and increasing HDL levels in the plasma of a mammal, in particular humans. The compounds are useful for treating coronary artery disease....

20050267216 - Levalbuterol hydrochloride polymorph b: The invention is directed to levalbuterol HCl Form B and methods of making the same....

20050267217 - Methods and devices for preventing transmission of sexually transmitted diseases: The present invention provides methods for preventing the transmission of HIV, methods for prophylaxis of HIV transmission and methods for reducing the risk of HIV transmission vaginally or rectally using compositions having at least one of polyquaternium, glycerin, methylparaben or proplyparaben. The invention further provides methods for inhibiting the transmission...

20050267218 - 4-hydroxymethyl-1-aryl-cyclohexylamine compounds: The invention relates to 4-hydroxymethyl-1-aryl-cyclohexylamine compounds, methods for their production, pharmaceutical formulations containing such compounds and the use of 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives for producing medicines which are useful, for example for treating pain. Related methods of treatment are also provided....

20050267219 - Enantiomers of n-desmethyl venlafaxine: The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses....

20050267220 - Methods for inhibiting activity of polyamine transporters: e

20050267221 - Use of curcumin and analogues thereof as inhibitors of acc2: The present invention relates to the use of curcumin or analogues thereof as modulators of mitochondrial fatty acid oxidation. More specifically, compositions of curcumin or analogues thereof can be used to inhibit acetyl-CoA carboxylase 2 (ACC2) thereby promoting fatty acid oxidation. Yet further, the invention relates to the use of...

20050267222 - Stabilized composition: The present invention provides a composition containing a substance being capable of supplying aldehyde-like substances to be used in the field of medicaments, cosmetics, hair care products, etc., that contains a low-molecular weight active substance the stability of which is impaired by the effects of aldehydes and a stabilizer having...